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ABSTRACT 
 
ENDOSCOPIC IMAGING ELASTIC SCATTERING SPECTROSCOPY  
FOR IN VIVO DETECTION OF LUNG CANCER 
 
 
Erik Herbert Lindsley, PhD 
 
 
University of Pittsburgh, 2005 
 
 
Elastic Scattering Spectroscopy is a promising in vivo technique for estimating the size of nuclei 
in epithelial tissues. Since increased nuclear size is a major morphopathologic sign of tissue 
progression towards cancer, this technique has been pursued by researchers who demonstrated  
cancer detection using it in an endoscopic point-test modality. For clear practical reasons related 
to future clinical use, we proposed and undertook expanding this spectroscopic tool into a true 
two-dimensional imaging modality. The overall objective of the research presented in this 
dissertation was to transform a promising spectroscopic test for early cancer detection in 
epithelial tissues into an in vivo/intrasurgical diagnostic imaging method, with lung cancer 
detection as the first application. The first specific aim was to develop an imaging system 
conceptually similar to the point-test one, but capable of rapidly acquiring a spectral image 
datacube. This was achieved, using novel hardware, software and optical design; all relevant 
performance parameters were met or exceeded. The second specific aim was the construction of 
a mathematical model for image content prediction, parameter evaluation, and optimization. This 
was also accomplished, and the intermediate (one-dimensional) results are consistent with the 
literature. The third specific aim was to verify the model against known targets (in vitro 
phantoms). This work was partially successful, and helped identify additional experimental 
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parameters that needed attention when building the imaging system. The fourth specific aim was 
use of the newly constructed system with consenting patients, in clinical procedures. In the first 
of these studies (30 patients), results were inconclusive because of all-negative biopsies, but 
functionality, operating room compatibility and adoption were demonstrated. In the second 
study, still ongoing, our imaging system was used to guide biopsies (21 patients), and results are 
currently being analyzed and compared to histopathology. Finally, since the initial system did 
not take into account all key parameters revealed during the progress of this dissertation, an 
improved next-generation system is specifically outlined. Overall, this work underscores the 
usefulness of advanced engineering in general and optical imaging in particular in constructing a 
new clinical diagnostic system aimed at early detection of cancer without use of contrast agents. 
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1.0 INTRODUCTION 
 
 
The detection, especially non-invasively, of cancer is a very ambitious goal - if it were easy, the 
decades of research already spent on it by numerous, dedicated scientists would have achieved 
more than partial success by now. Over the years, cancer has been studied at many levels: 
biologists have learned the telltale molecular/biochemical signs for various types of cancer; 
pathologists learned to recognize it at the tissue structural level; physicists and radiologists 
learned to locate more advanced stages of it using CT, X-rays, MRI, and PET scanners. 
Physicians learned to recognize physiological symptoms of a body suffering from advanced 
cancer. Each of these techniques identifies and attacks cancer at a given organization level and 
size scale (Molecular, Cellular, Tissue, , Organ, and Organism/Patient), yet almost none of them 
try to explicitly bridge any two or more of these scales. This dissertation is aimed at advancing 
this bridging idea by using light to discern microscopic properties (pathology) of bulk tissue in 
vivo/intraoperatively. The emphasis is on the theoretical, technological and application advances 
needed to image cancer early, non-invasively, and using no contrast agents. As the first foray 
into this approach, we focus specifically on early detection of lung cancer. 
 1
 2.0 BACKGROUND 
 
 
Cancer has just overtaken heart disease as the leading cause of death in the United States. Half of 
all men and one-third of all women in the U.S. will develop cancer during their lifetimes 
(www.cancer.org), and it is estimated that in 2005 cancer will kill 570,280 Americans -- more 
than 1,500 a day. Even if a fast, painless, and complete cure were found tomorrow, early 
detection would still be essential to treatment. Current methods revolve around inspection of 
biopsied tissues by a trained pathologist in a lab, not in the operating room or at the bedside 
(LaCroix et al.). Recent investigations into the application of optical imaging of tissue have 
focused around the so-called “optical biopsy,” which is a bit of a misnomer since the intent is not 
to remove tissue but to gain as much information as possible without actually performing tissue 
removal biopsy. In a more practical sense, compared to traditional biopsies, which only sample a 
few select areas, optical biopsies allow one to non-destructively “sample” much (if not all) of the 
surface layers in the tissue of interest. Additionally, an optical biopsy does not preclude the use 
of a more traditional biopsy—in fact, it can be used to guide this. 
 
 
2.1 MOTIVATIONS 
 
The “gold standard” for the diagnosis of cancer for many years has been the removal of 
suspicious tissue that is in turn analyzed by a trained pathologist, who then ranks the cancer 
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based on a variety of histological features and informs the physician, who then recommends any 
further treatment to the patient. There are several aspects to this “standard” that are undesirable, 
for a variety of reasons. For example, the site of the traditional biopsy is a single restricted area. 
A small cancerous lesion could lie 2mm away from the biopsy site and may in fact not be 
discovered for a long time. Selection of the site is often based on visible changes, and these 
changes often occur only after the cancer has reached a sizeable foothold in the body. In some 
cases, visual indicators are the only signs of possible cancer, and thus are not in themselves 
definitive. In these situations, with extremely aggressive cancers it is not unusual to prescribe 
preventive, “prophylactic” removal of the entire area despite the fact that there is a reasonable 
chance that such a procedure is unnecessary. Another undesirable aspect is that a piece of tissue 
must be removed to be analyzed—something one cannot do too often without destroying the 
surrounding tissue. This fact limits how often and for what medical reasons the procedure is 
performed.  
Focusing on the results themselves, the analysis that the pathologist performs is time-
consuming, often done at a remote location, and involves toxic chemicals. Furthermore, there is a 
disturbing lack of consistency of analytical results among pathologists (interobserver variations), 
and even between the same pathologist’s calls at different times (intraobserver variations). In the 
pursuit of a better quality of care, it would be desirable to improve upon the current “gold 
standard” to make it more objective and accurate in determining a given patient’s risk, in a 
timely fashion. The issues raised above can be grouped into four distinct areas that need 
improvement: 
 3
• In Vitro (in the lab) 
o Microscopic 
Improvements in this group are either indirect aids to the pathologist (such as 
automatic staining and specimen preparation machines), or direct aids to the 
pathologist (such as automated analysis software). 
o Macroscopic 
Using surgically removed tissue, automated systems using a variety of 
mechanisms try to localize suspicious areas for subsequent microscopic 
evaluation. Usually, the methods employed are optical in nature, as other 
approaches rarely have the spatial resolution of optical techniques. 
• In vivo (in animals in preclinical models, and in the patient in clinical applications) 
Moving the site of analysis to the patient can radically reduce the round-trip time for 
getting the desired results. This may also allow the physician to do more exploratory 
types of examinations or surgery or even guide the physician to suspicious areas which 
can then be more closely examined, biopsied and, ultimately, treated. 
 
This dissertation focuses on elastic scattering spectroscopy (ESS). It proposes to transform ESS, 
showing promising results in vitro and in vivo, when utilized as a point-test diagnostic modality 
(references), into a true diagnostic imaging modality. The use of this technique in an imaging 
modality is quite relevant to modern medicine, but, to my knowledge, has not been previously 
used for clinical purposes. In the case of lung cancer, the current standard-of-care calls for 
follow-up endoscopic procedures to check for a recurrence of the cancer after treatment. A 
device which aids the surgeon in his exploration of a patient’s lungs would be of great assistance 
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in advancing the standard-of-care. It even opens up the possibility that if the cancer recurrence is 
caught at a very early stage, a trivial lumpectomy could be performed through the endoscope, 
thus potentially saving the patient the pain and suffering associated with further cancer 
treatments such as chemotherapy. 
 While in vitro work is essential, fundamental research, all too often it fails to make the 
transition to in vivo. Moving from one to another entails many challenges:  
• Active biological processes that confound detection 
o Blood perfusion 
o Blood intrinsics 
o Normal cell division 
o Scarring 
o Cellular repair mechanisms 
o Tissue trauma 
• Light-matter interaction effects 
o Chromophore exhaustion (bleaching) 
o Mass-transport limits (quenching) 
o Scattering of photons in highly turbid media (regardless of source) 
o Reactions with other biological molecules present in the cell 
• Toxicology 
o Energy exposure limits (“cooking” the cells) 
o Contrast enhancer or other chemical marker toxicity limits (cells will only tolerate 
so much of a given chemical before normal cellular processes are disrupted) 
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o Long-term degradation or removal of any materials introduced into the cells (in 
some instances, the contrast agents have undesirable, long-term reactions with the 
cell processes). 
• Speed of data acquisition  
o Faster acquisition can minimize motion artifacts (since target is no longer fixed in 
place) 
o There is a limit to human patience (few people will wait minutes while the system 
collects data) 
o System noise (increases as speed increases) 
Additionally, there are a few challenges associated with simply moving from the laboratory to an 
operating room with real patients: 
• General engineering challenges 
o Device portability 
o Device resistance to normal “wear and tear” 
o Operating room regulations regarding aspects of the device (electrical isolation, 
kill switches, etc.)  
o Resistance to chemicals normally found in an operating room environment 
o Cleaning/Sterilization (device must be able to be sterilized between patients) 
• Analysis of the data (detection process) 
o Timeliness of results (data processing must be prompt, or even real-time if 
possible) 
o Intuitive representation of results for non-scientists (physicians are not 
comfortable making a diagnosis from just a sheet of numbers) 
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• Integration with existing medical practices 
o General resistance to change (new technique must yield more data or clearly 
better results than the old technique; simply because it is faster and cheaper will 
not mean quick acceptance)  
o Flexibility in deployment and usage (left versus right handedness, etc.) 
o Physician psychology 
o Internal Review Board approvals 
o Honoring patient privacy issues 
Many of these challenges were addressed by the work described in this dissertation, most were 
surmounted, but a few proved to be too resilient (see below). For a couple of these challenges, no 
contrast enhancers were used in order to avoid the associated toxicology challenges.  
 
 
2.2 LUNG CANCER 
 
For many years lung cancer has been, and continues to be, the most common fatal cancer in men 
and women in the United States and the rest of the world. One reason is due in large part to the 
prevalence of smoking in our societies, but this is by no means the sole reason. Lung cancer has 
many varieties, and their peculiarities will affect several aspects of this research. The areas from 
which primary lung cancer can arise are the epithelia, the soft tissues (parenchyma), and the 
pleura. Benign tumors are rare in lungs, and there is also the possibility that another cancer in the 
body can metastasize to the lung, but the frequency of both these types is relatively low when 
compared to the primary cancers. Cancers usually peak in the age range of 50-70 years, but 
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rarely occur at an age earlier than 40 years. There are a few that strike children, but these are 
special cases and are not the same cancers that strike adults. Most malignant tumors of the lung 
are called “bronchogenic carcinomas” because they originate in the bronchi, which is the part of 
the lung that occurs earliest in the branching pattern of airways. Bronchi are usually larger than 
2mm, but in practice few endoscopes can penetrate far enough into the lung to reach the end of 
the bronchi (this is true for HSIE, described later in this dissertation). Since the vast majority of 
the lung cancers  of interest here are bronchogenic carcinomas of the epithelial type, discussing 
the subtypes of epithelial cancers in more detail will be useful.  
Table 1: Epithelial Cancer Summary (adapted from Damjanov, 1996) 
Cell 
Subtype 
Freq. 
(%) 
Central 
Loc. 
(%) 
Nucleus 
(µm) 
Volume Scatt. Density 
Macro- 
Visible 
Adenocarcinoma 30    <10 4-7 Unch. Unch. Unch. Varies 
Adenosquamous 1-3    <10 4-7 Unch. Unch. Decr. Varies 
Carcinoids (child) <1 80 4-7 Unch. Incr. Incr. Yes 
Large Cell (Undiff) 7-15 50    ~12 Incr. Decr. Unch. Low 
Small Cell 15-20    >99 10-12 Unch. Incr. Incr. High 
Squamous cell 20-35 66 4-7 Unch. Unch. Decr. Varies 
  
The above table summarizes the following: subtype, its frequency among epithelial cancers, the 
chance that it will occur in the central part of the lung as opposed to the periphery, expected cell 
nucleus size, changes in the cell volume caused by the cancer, changes in the optical scattering of 
the cell, changes in the cell/collagen density, and whether the tumor causes macroscopic changes 
clearly visible to the naked eye. Combining all the above statistical information, it is worth 
noting that only about 22-35% of the lung epithelial cancers result in a dysplastic (enlarged) 
nucleus. Furthermore, the most frequent cancer (Squamous cell) is distinctive only in that it 
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forms keratinized cell groups (cells surrounded by excessive amounts of collagen, with 
subsequent reduction in the numbers of cells per volume of collagen). Macroscopically, 
keratinization is almost indistinguishable from scar tissue. It is also worth noting that modern 
endoscopes have trouble accessing more than about 10 branches into the lung by going in 
through the throat (or trachea). Thus, this research is inherently limited to cancers occurring in 
the central lung and hence is most applicable to large cell, small cell, squamous cell, and the rare 
carcinoid subtypes.  
 
 
2.3 HISTOLOGY OF LUNG CANCERS 
 
The human body can be investigated at various levels of complexity and size: Molecules, 
Organelles, Cells, Tissues, Organs, and Systems. For properly framing our research, it is 
important to outline the anatomy and physiology of the lung. It is part of the cardio-pulmonary 
System, and is an Organ made up of the four basic types of Tissues: 
• Connective: Underlies or surrounds other tissue, and normally has a role in structurally 
supporting other tissues. This tissue can have occasional cells trapped within it (e.g. 
migrating immune cells or matrix-building cells), but is normally dominated by a non-
cellular protein (collagen/elastin bundles) or mineral (ossified bone) matrix. 
• Epithelial: covers the body surface (skin/digestive tract, etc.), and lines all cavities inside 
the body (ducts, blood vessels, outer surface of organs) 
• Muscle: Contractile cells responsible for all types of movement in the body (locomotion, 
prehension, blood and air flow regulation, etc.)  
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• Neural: Receives, processes, and transmits information to control the various activities of 
the body (at all organization levels) 
The human lung is comprised of each of these four types of tissue in varying amounts, but given 
that our work is limited to areas that can be accessed by an endoscope, only the Epithelial tissue 
will constitute our focus; since most lung cancers arise from the lung epithelial tissue, this is 
certainly not too great of a limitation.  
 
Systems and Organs 
The pulmonary system is comprised of the upper and lower respiratory tract. The upper 
respiratory tract ( ) includes the nose (which cleans the breathed air, warms and moistens 
it, and filters large dust particles), the mouth (which only cleans and moistens the air), the 
pharynx (junction of the nose and mouth), and the larynx (which houses the vocal cords).  
Figure 1
Figure 1: Upper respiratory tract* 
 
 
 
                                                 
* Taken from “Essentials of Human Anatomy and Physiology, 3rd ed”, by John Hole, copyright 1989 William C. 
Brown Publishers. Reproduced with permission of The McGraw-Hill Companies.  
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The lower respiratory tract ( ) includes the trachea (which connects the larynx to the 
bronchi), the tree-like network of bronchi, and the alveoli (at the ends of the bronchi, where the 
actual gas exchange between the blood and the air occurs – see below). 
Figure 2
Figure 2: Lower respiratory tract (from Hole, 1989) 
 
 
 
 
The lung is filled with a network of passageways, ever decreasing in size, that carry outside air to 
a blood-gas exchange structure known as an alveolus (Figure 3). The larger passageways are 
called “bronchi” (“bronchus” being the singular form), and the smaller ones are called 
“bronchioles”. There are two main lobes of the lung commonly referred to as the “right lung” 
and the “left lung”, though some people have one of the lobes divided into two smaller lobes 
(with an extra secondary bronchi to connect them). Not shown in Figure 2 are the ribs, and the 
pleural cavity between the lung lobes and the ribs. Each of the lung lobes is surrounded by a 
membrane (the visceral pleura) that forms one side of the pleural cavity. The other side is formed 
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by a second membrane (the parietal pleura) that is connected (indirectly) to the ribs that form the 
thoracic cavity that the entire lung (as an organ) resides in. Each of these membranes secretes a 
fluid that, through surface tension, causes them to stick together but still be able to slide back and 
forth as needed. This arrangement allows for the fine structures of the lung to be dynamically 
supported by the ribs and other thoracic structures as it expands and contracts during normal 
breathing. 
   
 
Figure 3: Lung Alveolus (from Hole, 1989) 
 
 
These passageways of the bronchi and alveoli are completely lined with epithelial tissue. 
However, the bronchial epithelial tissue (mostly) has small hairs (or cilia), while the epithelia in 
the alveolus do not. One of the jobs of the epithelia in the alveolus is to secrete a mixture of 
lipoproteins that disrupt the surface tension of water so that the alveolus doesn’t collapse (and 
stick together like the membranes of the pleural cavity do). In the case of the bronchial epithelial 
tissue, some the cells (called “goblet cells”) produce the mucus (or phlegm) in large amounts, as 
shown in Figure 4. 
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Figure 4: Bronchial Epithelial Tissue (from Hole, 1989) 
 
 
In this figure, the “basement membrane” is where the cells connect to the underlying support 
tissues, and the cilia are exposed to the air. The cells shown here are two subtypes of “columnar 
epithelial cells”, which will be explained in greater detail in the following paragraphs. 
 
Tissue (Epithelial) 
 In vivo, cells are normally found in the company of other cells. While there are many different 
types of tissues in the human body, this thesis will be focusing on epithelial tissue. Epithelial 
tissue is found throughout the body, usually where there is a need to isolate one part of the body 
from either another tissue for biological reasons (excretory ducts), or from the outside world 
(skin, lung, intestine, etc). Simple epithelial tissue consists of one or more layers of epithelial 
cells, backed by connective tissues that provide structural integrity and a blood supply. Epithelial 
tissue may have more than one layer of epithelial cells, such as in the skin or the urinary bladder. 
In this multi-layer (“stratified”) case (rarely more than 7 layers), the epithelial cells undergo a 
maturation process by which the young cells push the older cells away from the connective 
tissues. “Stratified” epithelial cells have the capacity to maintain the isolation despite a large 
amount of stretching or distension, and so are commonly found in parts of the body such as the 
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urinary tract. Based on their shape, epithelial cells (and, by extension, the tissue) are classified as 
squamous (flat), cuboidal (cube-shaped), or columnar (cylindrical), as shown in Figure 5.  
 
Squamous?
Cuboidal?
Columnar ?
“Stratified”
Other Tissue
 
Figure 5: “Basic” Types of Epithelial Tissue 
 
Epithelial cells may have ancillary structures on their lumen surface (away from the connective 
tissue), such as microvilli (in the intestine) or cilia (in the lung). The tissue that supports the 
epithelial layer is normally a collagen matrix (connective tissue) filled with a variety of non-
epithelial cells (muscle tissue, immune cells, etc.). Technically, in the stratified case, there can be 
”Transitional” cells that are changing from one type to another, as in the case of the 7-layer 
“Stratified” epithelial tissue of the bladder.  shows an example of lung epithelial tissue 
with certain areas labeled. In the case of the lung, the epithelial cells of the bronchi have cilia 
”sweepers” to move small particles back towards the mouth out of the lung. Particles that cannot 
be moved (or accumulations of fluid) can collect and impair the function of the alveoli, leading 
to a variety of medical problems or possibly even death.    
Figure 6
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Figure 6: Lung Epithelia, with (A) lumen, (B) epithelial cells, an
 
Cells and Organelles 
While there have been over 200 types of cells identified in the
phospholipid bilayer called the “plasmalemma” of 8.5-10 nm
embedded in both the inner and outer surface. These protein
either surface of the plasmalemma. The interior of the cell is
and its surrounding cytoplasm. Inside each of these volumes,
reside. The following table (adapted from Campbell, 1993 and
a sense of the types and sizes of these structures. The numb
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† Nikon E800, Applied Spectral Imaging system  
d (C) cilia, (D) connective tissue† 
 human body, all are bounded by a 
 in thickness, containing proteins 
s extend as much as 10 nm from 
 normally divided into the nucleus 
 many organelles and substructures 
 from Perelman et al., 2002) gives 
er of each of the structures varies 
with the type, health, and life-cycle stage of the cell. The spectral, absorptive, and scattering 
characteristics of a given cell depend heavily on the relative numbers of its (size-wise) major 
(>1000 nm) and minor (<1000 nm) structures. For example, mostly passive cells have only a few 
mitochondria, while highly active ones, such as high secretion (liver) or muscle cells (heart), 
have more than a thousand. In such highly active cells, the cumulative effect of the “minor” 
structures often outweighs the influence of the “major” ones. 
 
Table 2: Some sizes of Major and Minor (mammalian) cell organelles 
Cell Organelle Sub-Structures Typical 
Shape 
Diameter (nm) 
Nucleus  Spheroid 1000 - 5000 
 Nuclear pores 
Prenuclear cisterna 
Ribosomes (on membrane) 
Heterochromatin (clump) 
Heterochromatin (filament) 
Heterochromatin (nucleosomes) 
Nucleolus 
Ribonucleoprotein particles 
Fibrillar centers 
   100 
    20 -     40 
    20 -     25 
  500 - 2000 
    30 
      4 
  500 - 1000 
    15 
    80 
Mitochondria  Spheroid   200 -   800 
 Inner Membrane 
Outer Membrane 
Space Between Membranes 
Cristae (outer membrane) 
       6 
      7 
    10 -     20 
    15 
Endoplasmic Reticulum  Tubes, Sheets  (cytoplasm) 
 Tubules 
Ribosomes (attached) 
     30 -   100 
    20 -     25 
Golgi Aparatus  Cisterne   100 -   400 
Lysosomes  Irregular   250 -   800 
 Embedded granules      20 -   100 
Peroxiomes     150 - 1200 
Cytoskeleton  Filaments  (cytoplasm) 
 Microtubules (0.2-2.5µm long) 
Intermediate filaments 
Microfilaments 
Cilia (2-20µm long) 
Flagella (10-200µm long) 
     25 
      8 -    12 
      7 
  250 
  250 
Inclusions  Lipids, glycogen, etc. None     20 -  500 
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As a point of comparison, the following table (summarized from Campbell, 1993) gives size 
information for some more general cell types found in biology, plus a few noteworthy organelles 
not found in mammalian cells. 
Table 3: Cell sizes and non-mamalian organelles 
Cell Organelle Typical Shape Diameter (nm) 
Typical Plant Eukaryote   Varies  
 Vacuole (+ Tonoplasts)    5000 -     8000 
 Cell Wall Flat     100 -     5000 
Typical Bacteria  Varies   1000 -   10000 
Typical Animal Eukaryote  Varies 10000 - 100000 
Mycoplasmas  Sphere/spheroid     100 -     1000 
Prokaryotes  Varies   1000 -     5000 
Chloroplasts Thylakoids, stroma    2000 -     5000 
 
 
 
2.4 SPECTRAL APPROACHES 
 
While there are several avenues for characterizing cancerous tissue that are now being actively 
used and/or explored, optical imaging - in comparison to techniques like ultrasound or X-rays, 
relying on single contrast mechanisms - holds the promise of several contrast mechanisms for 
observing pathological changes in tissue. These optical contrast mechanisms can broadly be 
classified into three types: absorptive, reflective/scattering, and fluorescent.  
• Absorption is the process by which photons are attenuated by the materials they pass 
through. The absorptive process is frequency/wavelength dependent, and thus, known 
materials can often be distinguished by how much each frequency is absorbed. Because 
of the severe attenuation in passing through several centimeters of human tissue, this 
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mechanism is often coupled with some sort of reflectance or scattering imaging. 
Additionally, the heat generated by the absorption of energy can be used to determine 
some bulk characteristics (Dark et al., 2000).  
• Reflectance/Scattering occurs when (1) light passes through a significant index of 
refraction change or (2) impacts on a scattering body. Depending on which direction the 
photons deflect, various geometric and light interference patterns can be observed and 
used to determine various bulk qualities. Examples of this are “back-scattering” (Utzinger 
et al.), and Mie scattering (Mie, 1908; Backman et al., 1999). In some cases, a situation 
can be set up to give additional characteristics to the backscattered light, such as in 
Raman spectroscopy (Kneipp et al., 1998); while photon use is inefficient in this case, the 
information content is high and chemical signatures are obtainable.  
• Fluorescence can either originate from intrinsic or extrinsic chromophores (Hellwig et 
al.). This process usually radiates photons in random directions, and thus image quality 
depends on collecting the radiated photons and on ascertaining when and where a given 
photon actually originated. Auto-Fluorescence Imaging is the use of intrinsic 
chromophores (Periasamy et al., 2001), whereas conventional Fluorescent Imaging adds 
additional (possibly targeted) chromophores to the tissue, such as molecular “beacons” or 
“tags” (Kricka et al., 1999, Li et al., 2001) or protein analogs (Giuliano et al., 1995) . 
The photon emissions are usually in response to direct-photonic excitation via lasers or broad-
spectrum lamps (technically, the photons that excite are not the same as the ones emitted), 
though the emission can be influenced by various factors, such as chemical environment or 
photon density. Furthermore, it is possible to add agents that affect more than one type of 
contrast mechanism simultaneously (Vargas et al., 2001). It is even possible to take the 
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coherence of the backscattered light to account (Wax et al., 2002), similarly to Optical 
Coherence Tomography (OCT) approaches. Finally, one can take any of the above contrast 
mechanisms and track how they change in time for additional information, such as dose delivery 
(Mourant et al., 1999). 
No matter which of these types of imaging and data analysis are considered, one of the key 
means of quantification is to obtain a spectral signature. This signature can have a variety of 
features, such as patterns in the amounts of light observed at different frequencies, changes to the 
original source light, and/or changes over time, and can be the result of complex interactions of 
molecules (such as energy transfer). It is well known that certain materials absorb or emit (when 
stimulated) in particular set of frequencies (Kricka et al., 1999). A collection of such 
characteristic frequencies associated with a single substance is called a “spectral fingerprint.” To 
date, investigations into the inherent spectral properties of cancerous tissue have tended to 
concentrate on the more bulk Spectral Response, but because of the highly scattering nature of 
human tissues (Kolarova et al., 1999), what emanates from the tissue is not easily interpreted. 
Past and current approaches can usually be grouped into the following: 
 
• Simple Reflectance (and Scattering): Shining “white” or monochromatic light on the 
tissue, and then detecting in the same frequency or frequencies. An extension of this is 
Scattering. In highly scattering media such as tissue, the resulting scatter-patterns can be 
analyzed to determine bulk properties (Backman et al., 2001, Hielscher et al., 1997). 
• Fluorescence: Shining light on the tissue at one wavelength, and then detecting in another 
wavelength (or simultaneously a set of wavelengths, see Andersson-Engels et al., 2000). 
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This can be repeated for sequentially for additional frequencies for additional information 
gain (Vaidyanathan et al., 2000).  
The two groups are normally limited to gathering information from less than 1 mm 
thickness of tissue. This limitation not withstanding, for many conditions such approaches can 
aid diagnosis considerably. Many investigators have shown that there is a correspondence 
between changes in the spectral fingerprints obtained and morphological changes in the cells, 
though the exact correspondences are often unclear (Kwong et al. (2001), Brewer et al. (2001), 
and Coghlan et al. (2001)). While examples of these first two groups have been around for more 
than two decades, new scattering-based techniques have been introduced relatively recently. In 
particular, the elastic-scattering spectroscopy (ESS) proposed by Dr. Irving Bigio is quite 
promising. Variations of this approach have been investigated separately by Dr. Michael Feld (et 
al.) and by Dr. Rebecca Richards-Kortum (et al.), with similarly promising results, including 
cancer diagnosis. However, until now, ESS was applied only as a point-analysis method, not as 
an imaging modality. 
 
 
2.5 DATA ANALYSIS 
 
Investigators in optical diagnostics often take either a modeling-based or an empirical approach 
to analyzing their data. The modeling approach tries to simulate light-tissue interactions using 
photonic propagation models (Welch et al.). These models are usually heavily physics-based, 
requiring a deep understanding of the mechanisms involved, and take a long time to generate 
results. The empirical approach usually consists of simply shining light on the tissue, recording 
the resulting spectrum and then trying to find discriminating patterns in what is seen. 
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Deconstructing the resulting spectral response back into its constituent fingerprints has proven to 
be very difficult. Some investigators have taken a more constructive approach where specific 
signatures are determined in isolation, searched for in the resulting spectrum, and then adjusted 
according to some model. Chief among these is oxy-hemoglobin and deoxy-hemoglobin 
spectroscopy, since blood is an omnipresent constituent in animal and human systems. More 
generally, the current challenges in spectral imaging of in vivo tissue are as follows: 
I. Tissue Intrinsics 
A) Interference from blood absorption: Oxy-hemoglobin has two strong peaks around 
540nm and 580nm, and this overlaps completely with Deoxy-hemoglobin, which has a 
peak around 550nm. Both generally absorb strongly between 500 and 600 nm (Palmer et 
al.). However, there are some frequencies where the absorption is the same for both, and 
are called isosbestic points. 
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 Figure 7: Hemoglobin Absorption Spectra (Adapted from S. Prahl) 
 
B) Variations due to blood perfusion: Tissue under examination ebbs and flows 
mechanically with blood pumped by the heart. This causes variations in spectral 
amplitudes from the changes in oxy-deoxy ratios and total volume. 
C) Many scattering bodies: Many of the larger intracellular organelles (in addition to the 
nuclei, such as mitochondria) readily scatter light because of index of refraction changes, 
and thus the resulting tissues become highly scattering, anisotropic media (Bigio et al., 
1997).  
D) Changes to cellular processes induced by light: In some cases, long term exposure to 
light levels insufficient to kill a cell outright can have long-term effects (Sroka et al., 
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1999), though keeping exposure times very short (sub-millisecond) seems to alleviate this 
problem.  
E) Chromophore bleaching: Depending on the chromophore, the observed 
autofluorescence emission can become weaker with the length of exposure to the 
excitation frequencies, and with cellular chemistry changes (Brooks et al., 1999).  
F) Overlapping absorption/emissions patterns: Separating out the components that make 
up a spectrum (in the presence of noise) can be very difficult, but some techniques to do 
this exist such as Chemometrics (Brereton, 1999), or Stokes/Excitation-Emission Shift 
Spectroscopy (Alfano, 2003). 
II. Intra-subject Variability 
A) Racial and age differences (melanin content of skin)  
B) Internal organs that normally are never exposed to daylight, such as the cervix 
(Brookner, et al.). 
 
All of the above will affect the resulting spectrum gathered by optical instruments. On top of 
this, the instrument itself may have its own “absorptive fingerprint,” though this can usually be 
fully characterized and compensated for well in advance of data collection. 
 
2.5.1 Spectral Analysis 
 
Analyzing spectral imaging data is not new—the military has been doing it for years with 
satellite reconnaissance imagery. But while those algorithms are very good at finding similar 
pixels, they are not very good at attaching meaning to the observed spectral responses. These 
spectral responses can be recorded in an imaging mode using a variety of tools, such as Acousto-
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Optical Tunable Filters, gratings, Fabry-Perot interferometers, Fourier Transform Spectroscopy, 
Liquid Crystal Tunable Filters, prisms, interference filters, etc. Data can be acquired either one 
frequency band at a time (band-sequential), or all the frequency bands for some sub-part of the 
image space (space-sequential). Regardless of how the spectral information is acquired, it then 
must be analyzed and converted into some form that emphasizes the items of interest in a 
perceptible way. Spectral analysis of several of the possible contrast mechanisms have already 
been applied with some success to the diagnosis of cancerous tissues: 
Bladder: Arendt et al., 1997 (Auto-fluorescence) 
Breast: Li et al., 2001 (Markers) 
Bladder: Mourant et al., 1995 (Elastic Scattering) 
Cervix: Brookner at al, 1999 (Auto-Fluorescence) 
Collagen: Tang et al., 2000 (Auto-Fluorescence) 
Colon: Rava et al., 1990 (Auto-Fluorescence) 
Epithelial cells: Backman et al., 1999 (Mie scattering) 
Head and neck cancer: Betz et al., 1999 (Auto-fluorescence) 
Lung: Shibuya et al., 2003 (Auto-fluorescence), Huang et al., 2003 (Raman) 
MS-2 Fibrosarcoma: Colasanti et al., 2001 (Auto-Fluorescence) 
Nose (Nasopharyngeal): Qu et al., 2000 (Auto-Fluorescence) 
Ovaries: Brewer et al., 2001 (Auto-Fluorescence, multiple) 
Stomach: Chwirot et al., 1997 (Auto-fluorescence) 
Most of the above investigations of spectral “fingerprints” have taken an approach whereby the 
spectrum (which contains many fingerprints all lumped together) is obtained, and then analyzed 
en masse. Examples of this analysis are:  
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• Simple Correlations 
o Emission-Excitation matrices (EEM): Monochromatic light is scanned across a 
range of frequencies (X-axis), and the obtained values (Z-axis) for each frequency 
(Y-axis) are plotted. Contours in the Z-plane (correlation) are then calculated and 
the peaks chosen as significant and used for further study. 
o Wavelength ratio matrices (WRM): Similar to the EEM above, the individual 
frequencies of the Y-axis are replaced by pairs of frequencies, whose value (Z-
axis) is the one divided by the other. Contours and peaks are chosen for further 
study.  
• Advanced Approaches  
o Principal Component Analysis (PCA): This is a multivariate procedure that 
essentially transforms a set of correlated variables into an uncorrelated set, and 
then selecting the variables with the greatest variability. This process reduces the 
dimensionality of the data set while retaining as much information as possible. 
PCA makes few assumptions about what is being analyzed, and this makes it a 
good general technique. However, often the resulting components have no easily 
ascribed physical meaning. 
o Pixel un-mixing (linear de-combinations): Given a set of “ideal” or assumed-to-
be-representative signatures, each pixel is classified as a linear combination of the 
ideal signatures. This classification can be “all or nothing,” but usually each 
signature is assigned a pseudo-color. (See Figure 8 for an illustration). 
o Clustering: Spectra are grouped together based on a ground truth, then the groups 
are used to make future predictions/classifications 
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o Fourier/Wavelet transforms: A set of basis functions are used to match against the 
signal, and the resulting set of correlations is then analyzed for significant 
patterns.  
More recent investigations have focused on pixel un-mixing, in spite of its limitation that the 
“ideal” signatures to be compared must be known a priori. Using a library of a few “ideal” 
curves, the picture can be pseudo-colored with intensities of a given color reflecting how much 
each of the curves contributes to the given pixel.  illustrates the results of this process, 
starting with a spectral cube. 
Figure 8
Figure 8: Brightfield image (left) and pixel unmixed (right, pseudo-colored with 5 identified spectral 
components of interest)  
 
   
 
 
2.5.2 Other types of light-based analysis in biological and medical applications 
 
There are many other types of imaging used in biological and medical applications that do not 
depend on spectral approaches. Without an attempt to artificially classify these, a list of the more 
broadly used methods is as follows:  
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• Optical Coherence Tomography (OCT): Using a distance reference, backscattered 
photons which travel more or less than the distance (hence deeper or shallower than the 
desired penetration depth) are ignored. This allows an image to be formed (ideally) from 
only the photons that have backscattered off of things at the desired depth. Morphometric 
information is derived from refractive index inhomogeneities, and 3-D images can be 
generated by scanning. 
• Second Harmonic (SH): Because of molecule anisotropy and localized electric field 
effects, this second-order effect causes some of the incident light energy to be scattered at 
twice the original frequency (Campagnola et al., 2003) 
• Raman Scattering (Raman): The perturbed electron may not return to its original energy 
state, thus gaining or losing a small amount of energy in this process. Statistically this 
occurs very infrequently, and results in an emitted photon that is not exactly the same 
wavelength as the original one. The resulting changes (originating in photon-phonon 
interactions) are based on - and therefore able to probe - the molecular structure of the 
material. The scattering is termed  Anti-Stokes Raman Scattering (in the case of a higher 
resulting energy state, but no charge shift) for the electron, and Stokes Raman Scattering 
(in the case of a lesser energy state). 
• Multi-Photon Excitation (MPE): In this technique, two (or more) photons striking the 
molecule nearly simultaneously, and this situation only occurs with sufficient photon flux 
density, at the focal point of a (microscope) lens. The energy of the MPE photons are 
combined in a non-linear way, having the effect of “adding together” the energy of the 
photons and thus being equivalent to the arrival of a photon with twice the energy (= half 
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the wavelength). Since this effect is usually confined to just the focal point of a lens, this 
allows for imaging very small volumes (~100 atto-liters; Webb, 2003). 
• Fluorescence (or Forster) Resonance Energy Transfer (FRET): Photonic energy is 
absorbed by the target molecule and is then transferred (non-radiatively, in a dipole-
dipole interaction) from this donor to a nearby (or bound) molecule (acceptor). The 
observed fluorescent signal is then generated by the energy recipient.  
• Fluorescence In-Situ Hybridization (FISH): When the target fluorescent molecule binds 
with another molecule, the binding physically changes the fluorescing part of the target 
molecule and thus causing a change in the observed fluorescent signal. This technique is 
commonly found in DNA assays, where the binding action of molecules targeting 
specific DNA sequences turns on the fluorescent signal, indicating the presence of that 
sequence.  
• Fluorescence Lifetime Imaging Microscopy (FLIM): The target molecule is first excited 
with a brief (laser) pulse. The energy remaining in the molecule will continue to be 
converted to a fluorescent signal, but will fade with time in a manner influenced by the 
various mechanisms present in the molecule for storing and transforming the energy and 
its environment. 
• Fluorescence Recovery After Photo-bleaching (FRAP): The target molecule(s) 
fluorescence signal is extinguished (bleached), and time to signal recovery is measured, 
effectively providing a concentration diffusion measurement.  
• Fluorescence Correlation Spectroscopy (FCS): Based on the fluctuations in the intensity 
over time (due to changes in the quantum yield or to the diffusion of molecules), it 
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becomes possible to estimate the number (or ratio) of molecules under observation, and 
to estimate the translational diffusion coefficient of a given fluorescent molecule.    
It should be noted that it is possible to effectively mix two or more approaches together for 
additional information. For example, MPE with either FLIM or FRAP. It is also possible to give 
some directionality to the fluorescent photons, or alter a given molecule’s fluorescent 
characteristics, by the introduction of nearby metal structures; this is commonly referred to a 
Radiative Decay Engineering (Lakowicz, 2001). The Mie scattering which will be covered in the 
next section is another example of a “perturbation” signal. 
 
  
2.6 MIE THEORY 
 
Fundamentally, Mie theory (Mie, 1908) is a mathematical expression of the interaction of Light 
and spherical scatterers. Mie theory covers both metal and dielectric spheres, both absorbing and 
non-absorbing. However, for the purposes of this dissertation, this discussion will be limited only 
to dielectric spheres, either absorbing or non-absorbing, but some details about mathematically 
representing light need to be covered first.  
 
2.6.1 Light (classical optics) 
 
According to classical optics, light can be expressed as an oscillating electric field (E) of two 
components (Ex and Ey) at right angles to each other. Fundamentally, both of these (sinusoidal) 
fields have the same amplitude (A) and frequency (ω). However, the two fields may not be in-
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phase relative to each other, and this difference in phase is called polarization (φ). 
Mathematically, 
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Note that it is also possible to instead write ϕ  as a change in the amplitudes Ax and Ay (and 
reflecting that change in the equations which follow), but for this discussion we will not use this 
option. The results, however, would be the same. 
For the purpose of this discussion, one can define the “phase lag” (τ) between two 
electric fields (i. e. R1 & R2) that have the same frequency, commonly the incident light and 
either a reflected or refracted component. Mathematically, 
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When light transitions from one substance (air, for example) into a dielectric substance (water, 
for example), some of the light is reflected (light that does not pass through the interface) and 
some is refracted (passes through the interface). How much light is reflected and refracted is 
dependent on the fundamental frequency of the dielectric, the angle of incidence, and the 
polarization of the light. Technically, the reflected light has its polarization rotated by 180 
degrees, but this is normally not important. The angle of the refracted light is determined by the 
phase lag between the incident light and the refracted light, and is otherwise known as the 
“refraction index” of “Snell’s Law.” A key thing to note is that it is possible to minimize the 
amount of light reflected for either the Ex or the Ey component (but not both at the same time) by 
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carefully selecting the angle of incidence. In some cases it is possible to minimize one of the 
components to have zero reflected energy at a certain angle, and this angle is commonly known 
as Brewster’s Angle. There is no angle for which all the energy (both components together) in 
the light passes through unaffected by the interface. 
This dissertation will assume that all planar electromagnetic wave-fronts ("light rays") are 
linearly polarized, and that two wave-fronts have “parallel” polarization if they share the same 
polarization angle or differ by 180 degrees. Likewise, two wave-fronts that differ by 90 or 270 
degrees will be considered “perpendicular.” While polarizations that are not multiples of 90 are 
possible, such details are beyond the scope of this analysis. For convenience, all “incident” 
wave-fronts will be considered to have a polarization of zero degrees.  
 
2.6.2 Introduction to Mie Theory for dielectric spheres 
 
Consider a non-absorbing dielectric sphere that allows a significant amount of light to pass 
through it, and is observed at a distance of several times the wavelength of the incident light (in 
the “far field”). When light (a planar, electromagnetic wave-front) strikes the sphere (point A, 
), some light is reflected off and some passes into the sphere. Figure 9
Figure 9: Sphere optical path 
 
B
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When the light leaves, again some light is reflected off the interface (point B, ) and some 
passes through. The reflected light continues back to the first interface, (point C, Figure 9), and 
again some light passes through and some is reflected. The resulting ”backscattered” light is 
much weaker than the original incident light, and because it has passed through a different 
medium there is a phase lag between it and the original incident light. This phase lag is based on 
the length of the path through the bead, and so the phase lag is dominated by the diameter of the 
sphere. If the diameter of the sphere is much larger than the wavelength of light, then the phase 
lag will become too large and the clear correlation between the incident and backscattered light 
will be lost, making the detection of this phase lag nearly impossible (usually appearing as 
“random” noise at the detector). If the diameter of the sphere is much smaller that the 
wavelength of light, the phase lag will become too small to be effectively measured (again, 
becoming “random” noise). However, for a given sphere diameter, there will be a range of 
wavelengths for which the lag is neither too short nor too long. This is the situation that Mie 
scattering focuses on. 
Figure 9
 The path that the light takes traversing the sphere is not a constant, and this variation 
translates to a spatially dependent phase lag around the sphere, relative to the incident light. 
Mathematically speaking, the relation between the incident wavefront (Ei) and the scattered 
wavefront (Es) in the far field can be expressed in terms of a scattering amplitude matrix S, 
which is a simplified form of a Mueller matrix that relates the corresponding Stokes vectors: 
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where k is the wave vector, ω is the frequency, and r is the direction of propagation of the 
scattered wavefront (in the spherical system of reference associated with the sphere). 
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In the case of a perfect sphere, both S3 and S4 can be assumed to be zero. It has been 
shown by Gustaf Mie that S1 and S2 are expressed as an infinite series of Bessel Functions based 
on the wavenumber, the diameter of the sphere, and the relative refractive index (more 
discussion on this to follow).   
  The scattered light pattern as a function of angle is shown for S1 and S2 in Figure 10.  
 
Figure 10: Example radiation pattern as a function of angle 
  
Assuming that the wavelength of light is on the same order as the diameter of the sphere, the 
pattern is controlled by two basic parameters. The first parameter is the ratio of the index of 
refraction of the outside medium to the bead material. The second parameter is the ratio of the 
Size of bead to the wavelength of the light in the medium. 
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Figure 11: Key Mie parameters 
These dimensionless parameters control the radiance pattern given the previous assumptions 
(bead diameter is similar in magnitude to wavelength). Non-absorbing spheres have real 
refractive indices, while absorbing spheres add an imaginary term to REFbead. If three of the 
above variables are known, the radiation pattern can be used to empirically determine what the 
fourth must be. For example, Figure 12 shows the resulting patterns for several example values 
of X as a function of angle assuming M=1.33. Dotted lines are S2 terms of the scattered light, and 
the solid lines are the S1 terms of the scattered light.  
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Figure 12: Radiation pattern variation as X changes 
 
 
Note that in this example, 180 degrees is total backscatter of the light back along the incident 
light and there is no difference between the terms. Likewise this is the case for total forward 
scattering (at 0 degrees). If one were to choose a single color of light and carefully choose the 
angle, it would be possible to distinguish the various values of X. A more robust way of 
distinguishing the patterns is either to sample several different angles, or several different 
wavelengths at the same angle.  
 Having shown that the phase lag of the light varies with the length of the path through the 
beads, and that the lag is dependent on two parameters M and X, it is now possible to ask what 
the signal might look like. First, is must be noted that both M and X are dependent on 
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wavelength, further complicating matters. Focusing first on this simplest case of light-bead 
interaction, assume that the incident light wavefront impinges at a right angle to the surface of 
the sphere, passes through the center of sphere, and exists the opposite side of the sphere. The 
situation described is often referred to as the forward scattering extinction case, shown by Van de 
Hulst (1957; page 176) to be characterized by: 
Qscattering = 2− 4p sin p+
4
p2
(1− cos p)
p = 2X M −1
 
It should be noted that Van de Hulst equation only predicts the resonant signal, and does not 
incorporate additional terms for the high-frequency “ripple” signal. This so-called “ripple” signal 
is apparent only if the Mie calculations are done in their full detail, and is shown in Figure 13 
(from Van de Hulst, 1957). Note that the amplitude of the “ripple” is small enough throughout to 
be (safely) ignored for the purposes of the work described in this dissertation.  
 
 
 
Figure 13: Example Q vs P plot (M=1.33, X increasing) ‡ 
 
 
                                                 
‡ Taken from “Light Scattering by Small Particles” by Van del Hulst, copyright 1981 by Dover Publications. 
Reproduced with permission of Dover Publications. 
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Also, the range of the M parameter is limited to about 1<M<2. However, for the scope of this 
dissertation, these limits are not exceeded. It should also be noted that the sinusoidal functions 
imply that a given bead size should yield an oscillatory signal as the frequency changes. More 
importantly, the p-parameter allows one to make an estimate of X if M is known and p can be 
estimated from the observed signal. Going the other way, treating p as a phase term, the period of 
the oscillations can be roughly estimated by assuming that the indices of refraction are constant 
over the range. However, because of the inverted wavelength term of X, k will be substituted for 
λ
1  in the analysis. This estimation yields the following equation for the “k-space periodicity”: 
))(1)(( mediumbead REFMdiamterk −=∆  
Since the conversion to k-space is not a linear one, equating it to the linear optical wavelength 
domain is non-trivial. Still, it can be used as an additional check for the results. For example, in 
the case of 1.0 µm polystyrene beads in water, the periodicity of the signal should be somewhere 
in the neighborhood of 0.50  in k-space. Furthermore, when comparing the signals of one 
bead of a certain diameter with the signal of a bead twice that diameter, the second signal should 
be half the period (twice the frequency) of the original signal.  illustrates this point by 
plotting the (ideal) Van de Hulst equation for spheres that differ only in diameter, by a factor of 
two: 
1−mµ
Figure 14
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Figure 14: Two spheres differing only in diameter (by a factor of two) 
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3.0 METHODS 
 
 
The following sections describe the main techniques and procedures used in this project.  
 
 
3.1 HARDWARE DEVELOPMENT 
 
For this project, a new type of endoscope was developed. This endoscope has the ability to 
rapidly scan the visible spectrum and acquire band-sequential images of tissue in vivo. The major 
design goals of the endoscope were as follows: 
• Distal end (the part that goes into the patient) needs to be able to fit within a 2 mm 
instrument channel of common endoscopes 
• System must be a non-contact, imaging scope (as opposed to a point-source tester) 
• System must capture all needed data in less that 0.5 seconds 
• System must be portable enough to take to the OR and able to be moved about the patient 
bedside by one person.  
The endoscope system that was built satisfies all the major design goals. A block diagram of 
it is shown in Figure 15.  
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 Figure 15: Block diagram of the HSIE 
 
 
Referring to the above figure, the endoscope consists of a normal commercial endoscope, with an 
additional 2 mm imaging fiber bundle (described in the next section) placed in the instrument 
channel; a high-speed monochromator (light source); a high-sensitivity, high-speed CCD 
camera; synchronization electronics; and a processing computer. The fiber bundle can be reoved 
as needed by the operator, and in fact can be used in any standard endoscope such as the one 
included with the commercial, auto-fluorescence-based Olympus “LIFE scope.” The entire 
system obtains reflection-ESS (Elastic Scattering Spectropy) images at 60-120 per second and 
collects and stores the data as well as biopsy notes. For each optical biopsy, 32 images of 
differing wavelengths are obtained, and grouped into a single “spectral cube” (a two-dimensional 
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image where each pixel is a set of intensities at the different wavelengths which comprise the 
third dimension, thus forming a three-dimensional dataset). The following Figure 16 is a picture 
of the actual HSIE endoscope in the operating room.  
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Figure 16: Hyper-spectral imaging endoscope components 
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3.1.1 Custom Fiber 
 
The custom fiber was built to our specifications by Instrument Technologies, Inc., since we had 
no experience in making the fiber sterilizable. The “fiber” actually consists of a single solid-core 
fiber for the illumination, and two 10k-fiber imaging bundles with matched polarizers and lenses 
(Figure 17, left) configured in an equilateral triangle within the tip of the “fiber.” This design 
allows both polarizations of light to be simultaneously carried back to the camera.  
 
 
 
Figure 17: Fiber tip (left) and camera view (right) 
 
 
 The camera’s field of view (Figure 17, right) only contains the two imaging bundles and allows 
both polarization images to be obtained in a single camera exposure. The imaging fiber bundles 
do not fill the cameras view and thus some pixels are unutilized. For the current application of 
the HSIE to lung cancer, low light levels have forced 4-by-4 binning to be used. The binning and 
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unutilized pixels ultimately result in each imaging bundle’s square (viewing area) to be reduced 
to 72 pixels by 80 pixels.  
 
3.1.2 Design and Implementation 
 
As part of this thesis, two versions of the master synchronizer were built (see Figure 18 and 
) and software for the Hyper-Spectral Imaging Endoscope (HSIE) was written. This 
HSIE was designed to obtain both (parallel and perpendicular) surface reflectance spectra at high 
speed. The master synchronizer aids in this by watching the camera and changing the frequency 
of the monochromator’s emitted light when the camera isn’t acquiring. Since the monochromator 
can switch in 2.5ms, the entire system is currently limited only by the camera’s acquisition speed 
of 120fps (8 ms/frame) and its light sensitivity. 
Figure 19
 The synchronizer employed a PIC Microchip™ microcontroller to store sequences of 
voltage changes, and digital-to-analog conversion circuitry to drive the Polychrome IV 
monochromator. The controller interfaces to the laptop computer through a standard RS232 
serial port, using the protocol documented in Appendix A. Since the monochromator must be 
sequenced very quickly in time with the camera, the voltage sequence is first downloaded in its 
entirety to the microcontroller’s memory through the slow serial port. The computer then 
instructs the sequencer to watch the camera, and then the computer collects the images. As each 
image is taken by the camera, the synchronizer watches for the time period when the camera 
“shutter” is closed and then changes the voltage output (=monochromator’s illumination 
frequency) in accordance to the stored sequence. Additionally, when the microcontroller is not 
watching the camera signals, it watches the external pedal. When the pedal is depressed (usually, 
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by the physician to initiate the optical biopsy), a code is sent through the serial port. When the 
computer receives the code, it initiates the spectral cube acquisition procedure. 
 
 
Figure 18: Master Synchronizer, Version 1 
 
 
 
Figure 19: Master Synchronizer, Version 2 
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Two versions of the synchronizer were built because a second HSIE was needed as part of a 
second grant. The second design improves on the first by adding some expansion capabilities, a 
newer version of the microcontroller, and isolating the analog amplifier section from the digital 
logic section to reduce noise on the output channel. Furthermore, new packaging variants of the 
older parts were available. Thus, version two of the controller offers improved control stability, 
smaller size, and increased memory for storing longer sequences. To summarize, the master 
synchronizer built for this research is what allows the system to operate at the desired frame 
acquisition rates. To increase the rate further, a faster camera would have to be used. 
 
3.1.3 
3.1.4 
Imaging Components 
 
To collect the images that would be analyzed, a fast-shuttered camera with good intensity 
resolution, good quantum efficiency, and hardware-pixel binning (for low light intensities) was 
needed. After much searching, a 12-bit, 60+fps camera manufactured by Cooke Corp. ( 
Sensicam Model 360) was chosen. With a fast camera, and equally fast (or faster) and selectable 
light source was needed. In this case, a fast monochromator (Polychrome IV, with an analog 
interface) was purchased from TILL Photonics, and slightly modified. This light source in 
particular was used because of its ability to change the frequency of the selected light in less than 
3 ms, thus allowing the illumination to be easily changed between faster camera exposures.  
 
Additional System Components 
 
The remaining parts of the HSIE were all obtained from commercial vendors. The computer 
laptop and docking station (Model C100 were purchased from Dell Computers Corp. The Model 
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C100 was chosen because its docking station could accommodate the two full-size PCI cards that 
were needed for the camera interface and second video card.  The 18” LCD monitor was 
obtained from Computer Discount Warehouse (CDW.com), and was chosen for good 
price/performance while being readable at a distance. The cart was purchased from Endoscopy 
Support Services, and was used to make the entire HSIE system mobile as well as for serving as 
a point of attachment for the camera arm. The camera arm was obtained from Special-T-Shop 
Manufacturing, and was used to allow the camera to be suspended near the doctor to compensate 
for the short imaging fiber length. 
 
 
3.2 EXPERIMENTAL VALIDATION (MODEL) SYSTEMS 
 
3.2.1 Cuvette-based Model System Development 
 
One of the first methods to test any optical sensing system it to employ cuvettes filled with 
known substances. Cuvettes should give a concentrated, unadulterated signal for comparison or 
verification purposes. The empirical results obtained from the cuvette work can be used to refine 
the systems or models, and to test fundamental abilities of the imaging system. More complex 
imaging tests can be done with the tissue phantoms. For these tests, cuvettes of varying 
concentrations of the model materials will be scanned by the HSIE and the resulting data used to 
refine the signal analysis for the phantoms. 
 For the first set of cuvette experiments, water and polystyrene bead suspensions were 
used. The reason for this is that the relative refractive index will be high for water + polystyrene, 
and according to the Mie theory, this should increase the backscattered signal. Agarose gel and 
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polystyrene beads were also used as this was the basis for the tissue phantoms and any 
significant differences needed to be identified early. In these experiments, specular reflection 
from the cuvette wall was avoided by placing the illumination/collection fiber at such an angle to 
the target surface that Fresnel (specular) reflections are avoided (in the case of the HSIE, 40 
degrees from the surface perpendicular should suffice). It should be noted, however, that this 
angle is not the angle between the illumination and collection fibers.  
 
3.2.2 Tissue Phantom Development 
 
Tissues phantoms are commonly used for a variety of testing purposes. One of the strengths of 
using phantoms is that their properties can be precisely and reproducibly. This allows a phantom 
with known properties to be used as a “ground truth” to test the imaging system and to help 
estimate system performance. Since epithelial tissue consists of two regions (epithelial cells and 
a connective tissue layer supporting it), it was natural to use phantoms that were built using a 
two-layer design. 
  
 
Figure 20: H&E stain of Lung lumen (left) and phantom diagram (right) 
 
 
Looking at Figure 20 above, the top layer simulates the epithelial cells, and the bottom layer 
simulates the diffusive backing tissue common in the human lung. In the case of the cancerous 
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lung tissue that can be imaged with an endoscope, and which may exhibit dysplasia, nuclei with 
a diameter of 4-7 µm are considered “normal,” and those in excess of 10 µm to be “abnormal.” 
Polysterene beads are available in certain sizes, and so a size of 4.3 µm (+-0.5um) were be used 
to represent “normal” nuclei, and a size of 10 µm (+-1um) will be selected to represent 
“abnormal” nuclei. Furthermore, to verify that the signal can be detected, additional beads of 0.5 
µm(+-0.05) and 1.0 µm(+-0.1) were used as well. In the results section, the same phantoms were 
used for the various spectral scans to make the results comparable with each other. 
 
3.2.2.1 Formulation 
 
The top layer was built by placing drops of a still-warm suspension of polystyrene beads and 
agarose onto the flat surface of the bottom layer and then allowing them to spread out and cool. 
This technique was first described in the paper by Bartlett et al., 2002. The bottom scattering 
layer preparation is based on the unpublished notes kindly supplied by Ousama A’Amar, 
working in Dr. I. Bigio’s lab at Boston University, and is formed by suspending TiO2 crystals in 
an agarose gel. The recipe that was used to make the phantoms is as follows:  
• Materials 
o Agarose (Pierce, 17850) 
o TiO2 crystals (J.T. Baker, 4162-01) 
o Polystyrene beads, purchased in a 2.5% suspension, 4.3um (17140-5) and 10um 
(18133-2) diameters, from Poly-Science, Inc. 
o A hot (70 degree Centigrade) water bath 
o Ultrasonic bath (sonicator) 
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o Petri dishes (or similar container to be used for the phantom) 
o Various small and large test tubes, and some mixing containers 
o Pipettes 
o Optional bead surfactant: HEPES (N-2-Hydroxyethyl Piperazine-N1-2-Ethane 
Sulfonic acid, from Research Organics, 6003H) at pH 8.0 
 
• Building the bottom (scattering) layer 
To build the bottom layer, mix H2O with the Agarose, and then mix in TiO2 into a slurry. For 
each 1ml of bottom layer material, 10mg of Agarose and 1.6mg of TiO2 is needed. (For the 
phantoms built to test the HSIE, 3ml of bottom material was used for each phantom. Thus 3ml 
H2O, 30mg of Agarose, and 4.8mg of TiO2 was used for each one.) Prior to mixing the H2O with 
the Agarose, 1-2ml of the H2O was separated and mixed instead with the TiO2 to form a slurry 
and sonicated. The slurry is then placed in the hot bath. Mix the H2O with the Agarose, heat in a 
microwave until it boils, making sure that the Agarose mixes well and does not settle to the 
bottom of the container. The hot mixture should be clear and not cloudy at the bottom. After it 
cools down for a few seconds, mix with the slurry and sonicate. If the white slurry turns gray, the 
mixture was too hot. In this event, the Agarose and TiO2 crystals have reacted and the step will 
have to be repeated. Finally, place the container into the hot bath to keep it warm while 
transferring the proper amounts into the petri dishes. Let the bottom layers cool until firm, and 
then place in a refrigerator until cold. The result is illustrated in . Figure 21
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 Figure 21: Bottom layer constructed 
 
 
 
• Building the top layer 
To build the top layer, one needs to make the agarose gel, mix in the polystyrene beads, and then 
pipette drops onto the cold bottom layers. Some bead suppliers include a surfactant that helps 
prevent the beads from clumping together. (If the beads lack a surfactant, use the HEPES instead 
of H2O as the buffer for this Gel.) Again, calculate the volume of Gel needed per phantom. The 
4.3um beads need a ratio of .025ml to 1 ml of Gel. The 10um beads need a ratio of .050ml to 1 
ml of Gel. Mix in the beads as was done for the slurry, using the beads instead of the slurry. 
After sonicating, quickly pipette the mixture onto the bottom layer of each phantom. Since the 
volume of the scattering layer is much less than that of the bottom layer, its thermal mass is 
much less and so will quickly cool to yield the appearance illustrated in Figure 22. 
  
 
Figure 22: Bottom+Top Layer (note the dots on the surface) 
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A weakness in the design of the phantoms is that the resulting top layer is between 1-7 cell 
“layers” deep. Some variants of the above phantom were explored in an attempt to reliably 
construct a single “cell layer.” The first variant placed a thin film of water on top of the top layer. 
The second variant used a microscope cover slip to squash the top layer flat onto the bottom 
layer. In both cases, the additional specular reflections from the light of the HSIE tip (from the 
air-glass-gel interface) made imaging impossible and so were ultimately rejected.  
To determine what concentration of beads was to be used, a titration was done to see what 
ratio of beads would not clump together. The materials and equipment normally used for 
constructing the phantoms are two pipettes (0.40ul and 1ul), 4 test-tubes, and a 1 litre container 
for the hot bath. As a form of quality control, the top layer is also applied to a regular microscope 
slide (see Figure 23), which can then be quickly checked for abnormalities in the beads (thermal 
damage, etc.) without the need for trying to image the phantom on a microscope. 
 
 
Figure 23: Quality-check slide 
 
 
The phantoms should be stored for at least a few hours in the refrigerator before use. Phantoms 
can be stored for up to 3 weeks in the refrigerator before a significant amount of water has 
evaporated from the gel. For the testing of the HSIE, the phantoms were normally used within 3 
days of manufacture. To facilitate titration and other experiments requiring a large number of 
phantoms, 96 well plates made of black plastic (shown in ) will be used. Figure 24
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 Figure 24: Black, 96-well plate 
 
 
These plates have a clear plastic bottom that we spray-painted black to absorb all light that might 
reach the bottom of the well. 
 
3.2.2.2 Verification 
 
The model described was verified by micro-dissection and microscopic imaging to verify the 
layer formation and to ascertain that the beads spread out relatively evenly and did not clump 
together.  
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 3.3 SIMULATION DEVELOPMENT 
 
A model was developed to predict what the HSIE should be seeing for a given target, and then 
the results were compared to what was observed by the system. Assuming the model is 
sufficiently accurate, the system can then be improved by exploring parameter changes through 
the model rather than building a new device each time. The model was tested against the tissue 
phantoms described above.  
 
3.3.1 Summary of relevant prior work 
 
Dr. I. Bigio, followed by others, has initiated an area of research applying Mie scattering (of 
nuclei) to determine cell/tissue morphology. Mie scattering is based on predicting the effects of 
(roughly spherical) scattering bodies on (typically) monochromatic incident light. Since the 
range of wavelengths that the HSIE is capable of is within an order of magnitude of the diameter 
of the scattering bodies of interest (cell nuclei), the resulting scattering effects are wavelength-
dependent. This wavelength dependence should give a contrast mechanism that should allow one 
to infer the average size of nuclei that make up a pixel in the resulting spectral cube. 
Dr. Bigio’s Elastic Scattering Spectroscopy (ESS) approach is a combination scattering and 
absorption measurement, of which Mie scattering (in particular, the forward-scattering 
extinction) is a component of the final signal that is analyzed. The ESS approach normally 
involves a touch probe, where the illumination and collection fibers are located in close 
proximity. The collected light is then sent to a spectrometer, and then resulting spectra analyzed 
in a variety of ways (Bigio, et al., Mourant, et al.) to obtain classes of spectra associated with 
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various morphological conditions. These ESS systems have been used in human trials by Dr. 
Bigio and others, and have achieved high sensitivities and specificities in certain cases.       
Some of Dr. Backman’s (et al.) research is also related to what this dissertation will be 
attempting so far as a point-detection modality is concerned.  Backman proposes Polarized Light 
Scattering Spectroscopy (PLSS), where by the reflected signal from cells ex-vivo was split into 
the parallel and perpendicular components and then subtracted from each other in an attempt to 
extract the Mie signal from just the surface. In this experiment, broad-band fiber optic white light 
(450-750nm) source was used to illuminate a 2 mm-diameter circle of the tissue sample, and the 
light then collected and subsequently split into both polarizations before entering a spectroscope. 
The resulting spectral data was then combined (with a few fudge factors) to extract the Mie 
signal. Samples of both cancerous (T84 Malignant cell line) and normal colon tissue were 
analyzed, and characteristic signals were obtained for each class of sample (cancerous and non-
cancerous). These results were verified using microphotographs. The obtained signals were 
observed to have oscillating components in the spectrum, and it is surmised that these are the 
Mie components. The PLSS approach differs from the HSIE in the following ways: 
• The HSIE uses glass fibers to transmit and collect the light from the target tissue 
• The HSIE illumination is a series of mono-chromatic colors, rather than a broad-spectrum 
“white” light. Additionally, the spectral range of the HSIE is shifted toward the blue, 
relative to that used by Backman et al. 
•  The PLSS is a pure backscatter measurement, but the incident light was 15 degrees off 
the perpendicular of the target. The HSIE is a near-backscatter measurement (7 degree 
separation between illumination and collection) 
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Gorgekoudi et al., have used PLSS as part of three-modality (autofluorescence, diffuse 
reflectance, and light scattering) point-probe system in detecting and characterizing cervical pre-
cancers in vivo. 
 
3.3.2 
3.3.3 
Mie Scattering Calculation Code 
 
The Mie code used by the simulation (See Appendix) to calculate the ideal curves was based on 
the (Fortran code) example given in Bohren’s book. This code was converted into an equivalent 
Matlab program and verified using test parameters and output that were also given in the book. 
The ideal curves were calculated using a 1nm step size over the entire spectral range of interest 
for each of the target bead diameters. The ideal curves were then used as input into the optical 
ray-tracing simulation of the HSIE. 
 
Ray simulation 
 
To predict what the HSIE should “see,” several key parameters needed to be determined. The 
optical geometry of the system at a given distance determines the angles of the scattered light 
that would be recorded by each imaging pixel of the camera. This simulation calculated the 
observed intensity of light (either parallel or perpendicular, as appropriate) for all voxels of the 
target. Using standard optical ray tracing techniques the model estimates the limits of the 
contributions of each imaged pixel, assuming the sole source of illumination is from the HSIE's 
illumination fiber. These results are computed for both the perpendicular and parallel parts of the 
final image (complex values) and then combined yielding a complex result. Taking the 
magnitude of the result gives the final values one would expect to see.  
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 3.4 CLINICAL TRIALS 
 
We developed the entire imaging elastic scattering spectroscopy approach in the hope that, in a 
not-too-distant future, it can be developed to address unmet needs in the clinic. Specifically, an 
endoscopic implementation that would improve detection of cancer and pre-cancerous conditions 
intrasurgically was a logical path to pursue.  
An opportunity arose where by joining an existing study, the HSIE system could be used to 
obtain spectral information from human subjects in the operating room. The existing study was a 
detailed investigation into both the diagnostic power of Laser Induced Fluorescence Endoscopy 
(LIFE, Olympus Corp.) as compared to the current (gold) standard, and into the biochemical 
realm of cell markers for lung cancer. 250 patients (at high risk for lung cancer) were enrolled in 
the main study, with each patient receiving one or more bronchoscopic interventions that 
consisted of a diagnosis by use of (a) white-light (gold standard), (b) the autofluorescence-based 
LIFE imaging system (Olympus Corp.), and (c) intrasurgical tissue sample acquisition for 
subsequent cell-molecular analysis. We proposed that in addition to the above procedures, in 
vivo data could be collected with the HSIE. After it was determined that this would not 
negatively influence the main study, University of Pittsburgh Medical Center Internal Review 
Board approval was obtained to add HSIE onto the original study (See Appendix B for more 
details).  
Patients that were to be imaged by the HSIE were a subset of patients from the main 
study who were being followed after successful treatment for lung cancer. These patients had 
failed a subsequent sputum test and were to receive a follow-up endoscopy procedure. For these 
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(consenting) patients only, the HSIE was also be used to collect spectral information about the 
biopsy sites. The spectral information could then be correlated with the results reported for the 
site by Pathology.  
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 4.0 RESULTS AND DISCUSSION 
 
 
The following sections report and discuss the results of the techniques described in section 3.  
 
 
4.1 PARTICLE SUSPENSIONS 
 
4.1.1 Construction and test setup 
 
Standard 5-uL plastic cuvettes (optically clear over the visible light spectrum) were used to hold 
the material being scanned. The cuvette was placed in a harness (see Figure 25) that allowed the 
distance from the fiber tip to the 1mm thick wall of the cuvette to be controlled. The scans were 
performed at 40 degree fiber incidence to avoid specular reflection, at a nominal distanced of 
6.5mm such that the 10mm focal point of the optics fell just inside the cuvette wall. The angle 
between the illumination and collection fibers was 173 degrees (backscattered) light. All scans 
were repeated 64 times, and then averaged to reduce random noise. Cuvettes were filled with 
either a 1:50 or a 1:100 dilution of beads and either H20 or Agarose (gel). All beads were 
initially 10% by weight, and then diluted to the specified ratio. Beads of the nominal diameters 
of 0.5 µm and 1.0 µm were chosen for this experiment because of the factor-of-two relationship 
should be apparent in the observed signals.    
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 Figure 25: Cuvette data acquisition setup 
 
 
4.1.2 Results 
 
This first set of figures covers the cuvette-based experimental data, “white” normalized using 
system-wide averaged spectra.  
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 Figure 26: comparison of H20+beads at two concentrations 
 
 
From a physics point of view, the S1 (parallel) component contains information about both the 
surface of material and the deeper layers, while the S2 (perpendicular) component just contains 
information about the deeper layers. Figure 26 compares H20+beads at the two concentrations, 
showing both the parallel (S1) and perpendicular (S2) signals obtained. The dotted lines 
represent a 3rd order polynomial fit to the signal to compensate for unknown scattering events as 
well as emphasize the oscillatory signal. First, it should be observed that there is in fact an 
oscillatory signal, and that it differs for different diameters. Second, there is a rough factor-of-
two relationship in the count intensities, commensurate with the factor-of-two dilution 
relationship. Using the polynomial fit to extract oscillatory part of the signal yields interesting 
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patterns in the Fourier domain. The use of the Fourier Transform in analyzing single scatting 
events is common in the literature, and more recently has been termed Fourier Transform Single 
Scattering Spectroscopy (FTSSS) by Amelink, et al. The following four figures comprise K-
space plots (commonly used in chemistry applications) make the oscillations clearer to the eye, 
accompanied by a fast-Fourier transform (FFT) of the signal. The top part of the plot is the 
residuals (deviation) from the curve fitting, and the bottom part is the FFT of the same data. The 
peaks in the FFT should correspond to the diameters of the beads. 
 
 
Figure 27: S1 signal for H20+beads at 1:50 dilution 
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Figure 28: S2 signal for H20+beads at 1:50 dilution 
 
Figure 29: S1 signal for H20+beads at 1:100 dilutions 
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Figure 30: S2 signal for H20+beads at 1:100 dilutions 
 
 
It should be noted that as the dilution increases the signal gets weaker the amplitude of the 
oscillations also get weaker, but the peaks at integer phase-distances remain unchanged for the 
corresponding signal (either S1 or S2).  This next set of figures compares the signals for a 1:100 
dilution of beads suspended in either H2O or Agarose (AGR). 
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 Figure 31: Comparison of beads and either Agarose or H20 at 1:100 dilution 
 
 
As expected, the amplitude of the signal is further reduced by the switch to Agarose (change in 
relative indices of refraction). This amplitude reduction makes the FFT analysis tougher in the 
case of Agarose suspensions, but the peaks are still distinguishable, as shown in the next two 
figures. 
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Figure 32: S1 signal for Agarose+beads at 1:100 dilutions 
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Figure 33: S2 signal for Agarose+beads at 1:100 dilutions 
 
The results for Agarose have the characteristic peaks continue to appear in the S1 signal. The S2 
signal exhibits some unexpected shifting which may be due to a variety of factors, including low 
sampling, or simply noise from the low signal. While the phase distance does not exhibit the 
desired factor-of-2 dependence, this may be simply a sampling resolution error, but it may also 
be from the fact that an average system response was used instead of a pixel-by-pixel response. 
This possibility will be explored in the next paragraphs.  
For the pixel-by-pixel white normalization, a Spectrolon™ target was used to provide 
pixel-by-pixel white normalization curves for the entire field of view of the HSIE. In the case of 
tissue phantoms, we are only interested in the surface of the phantom. Intuitively, the parallel-to-
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the-scattering-plane signal contains information from the surface + depolarized information from 
the deeper structures. The perpendicular-to-the-scattering-plane signal contains information from 
deeper structures that we have little interest in. Theoretically, one can be subtracted from the 
other, leaving just the information about the surface. In engineering practice, this is difficult to 
achieve proper cancellation due to light collection issues (the scattering planes for each imaging 
bundle are technically not the same, imaging bundle alignment, lens alignment, etc.) and parallax 
issues. With regards to the phantom data, performing the subtraction made things significantly 
worse, not better. Thus, the results presented here will be limited to the S1 signal.  
 
Figure 34: S1 signals for tissue phantoms at 1:100 bead dilutions 
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Applying to the results in  the same procedure used for extracting the signals in 
 yields the following 4 figures. 
Figure 34 Figure 
31
 
 
Figure 35: New S2 signal for H20+beads at 1:50 dilutions 
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Figure 36: New S1 signal for H20+beads at 1:100 dilutions 
 
Figure 37: New S1 signal for H20+beads at 1:50 dilutions 
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Figure 38: New S1 signal for Agarose+beads at 1:100 dilutions 
 
 
The most significant difference here is that the peaks are now located consistently at a phase 
distance of 2 and 4, as opposed to the previous 3 and 4 (again, integer rounding error is the most 
likely culprit). The new peaks now have the factor-of-two relationship that was expected, and the 
signal amplitudes are slightly greater, leading to the conclusion that the pixel-by-pixel white 
normalization is necessary to reliably extract the Mie signals.  
 To summarize, it is possible to distinguish the beads from each other using FFT to find 
distinctive signal peaks. However, the spectral resolution of the HSIE is not sufficient to obtain 
clear separation of the peaks. Furthermore, the signal-to-noise ratio of the observed signals is 
low, and this will make detection and interpretation more difficult as we move on to the more 
complicated physical models (tissue phantoms). 
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 4.2 BEAD-BASED TISSUE PHANTOMS 
 
4.2.1 Construction 
 
Using titration, a dilution of 1:80 for 4.3 µm and a dilution of 1:40 for the 10 µm beads (using 
HEEPS as an anti-clumping agent) was found to yield virtually clumping-free distributions of 
beads. However, real epithelial tissue has a tighter packing (with no clumps) than could be 
achieved with the beads.  
 
 
Figure 39: Microscopic image of the top layer of a 10um-bead phantom (with one “diploid”) 
 
 Figure 39 shows a miscroscopic view of the top layer of a 10um-bead phantom, viewed from the 
direction that the HSIE would be imaging using a 40x air objective. There is virtually no 
clumping, with only the occasional “diploid cell”-like touching of two beads. These “diploid” 
items could have been eliminated/neglected, but instead they were retained here as a 
representation of a dividing cell. 
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4.2.2 Microscopic Imaging of Tissue Phantom to Verify Known Structure 
 
For the first verification, two-layers were checked for through the excision of a small sliver 
of a phantom, which was placed on a slide and then imaged. Figure 40 was the result, using a 
5x air objective. 
 
Air 
Upper Layer 
Bottom Layer 
Figure 40: Side view of a 10um phantom 
 
 
Looking at the cross-section of part of the phantom, the air, upper layer, and bottom layer have 
been labeled in the image, and a yellow line approximates the border between the upper (beads) 
and lower (scattering) layers of the phantom. The arrow indicates a 10um bead in the upper 
layer.  
 
4.2.3 HSIE Verification 
 
For the second verification, a 96-well plate was prepared with several different phantoms in 
certain patterns. For each pattern, X=1.0 µm bead phantom, Y=0.74 µm bead phantom, and 
Z=0.5um bead phantom. In the patterns, data was collected at a 40 degree incident like in the 
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cuvettes (see ) to avoid specular reflections. The scans were repeated 64 times, and 
then averaged to remove noise. All data has been adjusted to a camera exposure time of unity. 
Figure 25
 
Pattern #1 Results 
The goal of this pattern ( ) was to test how increasing the top layer concentrations affect 
the results: 
Figure 41
Figure 41: Bead layer concentration test grid 
Bead 
Concentrations
1:25 1:50 1:100
X X X 
Y Y Y 
 
Beads 
Z Z Z 
 
Each well was scanned individually, and the results summarized below. Curves were taken from 
the optical center of the imaging field of view.  
 
Figure 42: Top (bead) layer titration signals showing White normalized signals vs. Wavelength(nm)  
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The above figure shows the actual signal observed, with the dotted line polynomial fit included 
for clarity. These signals have a certain consistency as the concentration of beads is varied 
(shown in Figure 43), which is a desirable result. 
    
 
Figure 43: Comparison of top (bead) layer signals by bead size 
Figure 43
 
 
 groups the signals by bead size, and the signals are similar for each level. The 
magnitude of the separation for each concentration signal is not consistent, but this lack of 
consistent separation does not affect the subsequent signal extraction.  
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 Figure 44: Comparison of top (bead) layer signal deviation of fit 
Figure 44
 
 
This final figure of the set ( ) shows that the differences in the concentration of beads 
does not seem to significantly affect the signal, and that the signals can be differentiated at all 
concentrations. Furthermore, the top plot has roughly 4 signal peaks, the middle plot has roughly 
3 peaks, and the bottom plot has roughly two peaks. This is consistent with the factor-of-2 
difference between the top and bottom bead diameters, and the factor-of-1.5 relationship for the 
middle plot.  To summarize, while the concentration of beads does affect the signal-to-noise 
ratios, it does not significantly affect the observed oscillatory signature.  
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 Pattern #2 Results 
The goal of this pattern ( ) was to test the how increasing the bottom scattering layer 
concentration affects the results: 
Figure 45
Figure 45: Bottom layer concentration test grid 
 
Background 
Concentrations
1 1.5 2 
X X X 
Y Y Y 
 
Beads 
Z Z Z 
 
Figure 46: Bottom layer titration signals 
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Figure 46 is a summary of signals observed from the three concentrations (W1, W2, W3) of the 
bottom layer scattering components (16 mg, 24 mg, and 32 mg of TiO2 respectively). The upper 
left plot shows that there is no oscillatory signal contribution from the bottom scattering layer. 
The remaining three plots show the observed signal for each of the three concentrations, grouped 
by the bottom layer concentration.   
 
 
Figure 47: Comparison of signals by bead size 
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Figure 47 groups the observed signals by bead size, and as was seen in Figure 43, there is not a 
consistent magnitude shift depending the concentration changes. Extracting the oscillatory 
components, as before, yields the following: 
 
Figure 48: Comparison of bead signal deviation of fit for a given bottom layer 
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Observations that were made for pattern #1 can be also applied to the results in , so to 
summarize the results of Pattern #2, the influence of the concentration of the TiO2 bottom layer 
seems to be minimal on the S1 signal. This is consistent with the known physical fact that the S1 
signal is comprised primarily of information about a depth of only a few wavelengths (for each 
color of light).  
Figure 48
 
Pattern #3 Results 
The goal of this pattern was to test the ability to spatially resolve areas of different sized of 
beads.  This pattern was a 3x3 grid with X and Z arranged in the shape of the letter “C”: 
X X X 
X Z Z 
X X X 
Figure 49: "C" test pattern 
 
 
It was initially though that only a 3x3 grid would be able to be seen by the optics of the HSIE, 
but in fact, only 4 wells were able to be successfully focused upon. Consequently, only a 2x2 
section (XZ;XX) and a 1x2 section (XZ) of the grid were in fact imaged. Also, a separate 
phantom for each X and Z were also scanned to be used as classifier validations. The images 
were then analyzed pixel-by-pixel, and a false-color image based on the dominant oscillatory 
component of the spectra was generated. 
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 Figure 50: Test for Z classification 
 
For the Z classification, the signal was fairly reliably classified, but a couple of pixels at the top 
were misclassified. The signals from the surrounding areas were too weak to be confidently 
classified. 
 
 
Figure 51: Test for X classification 
 
In  the case of the X classification, some of the signals in the center field of view were too weak 
to be confidently classified (SNR<1.2).  
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 Figure 52: 2x1 grid classification 
 
For this test, the upper left region should be blue, and the lower left region should be red. Again, 
signal strength was a big factor in confusing the classifier. 
 
 
Figure 53: 4x4 classification 
 
 
In this test, the bottom area should be red, and the top, left, and right regions should be blue. The 
center area is the flat-black plastic that separated the wells, and should not have been classified 
as wither red or blue.  There is a serious parallax effect evident in this image, and this violates on 
the previous assumptions that there is no significant change of distance over the field of view. 
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The results from the above figures were not as strong as expected. Some possible reasons for 
these unexpected results are: 
• Beads were not of sufficient depth/density to generate a strong signal 
• Scattering layer is “too efficient”, destroying the signal 
• Light was insufficient in intensity generate a strong signal 
• Spectral resolution of the system is too low (resulting in few points for the FFT) 
The above images demonstrate that it is possible to detect different beads diameters in an 
imaging modality, the signal is very weak and suffers from this fact in a variety of ways. 
Furthermore, the distance and parallax issues cannot be ignored. 
 
 
4.3 SIMULATION OF HSIE 
 
For the model, it was assumed that the target being observed was in focus and consisted of only 
one size of beads that were uniformly distributed throughout the image volume. The first stage of 
this model estimated the angles between the illumination fiber and the imaging fibers, taking into 
account the numerical apertures of each. As the distance increases, the number of fixed-sized 
points of the target that are visible increase as would be expected. It should be noted that the tip 
optics have a focal length of 10mm (third set from the top), and that the calculations do not 
include the fact that at other distances the lenses will be out of focus. If the model were to stop at 
this point it would yield the following “predicted images” using the polarity calculation (for 
1.0µm diameter): 
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 Figure 54: Ideal HSIE view for 1.0µm (intermediate result) 
 
 
Referring to Figure 54, the top part of the figure is a spatial image view of the ideal “target.” The 
overlapping, disk-like contours arise from a combination of the two points of view (parallel and 
perpendicular imaging fibers) and the angular step-size of the curve library (0.1 degree). The 
bottom part of the figure is a graph of three distinct areas taken from the spatial image. These 
areas were chosen to illustrate how the signal can change through the field of view. The colored 
boxes correspond to the location of each curve in the image: the center (black, solid line), the 
lower right hand corner (green, dotted line), and half-way in between (red, dashed line).  
However, the model does not stop there and instead continues by estimating the limits of the 
contributions of each imaging pixel by integrating over both the solid angle of the illumination 
 84
fiber (NA=0.45) and the solid angle of the imaging fiber’s lens (NA=0.35). These results are 
computed for both the perpendicular and parallel parts of the final image and then combined 
using the polarity calculation. The model was further increased in its complexity with the 
inclusion of the fact that the light source used for the current HSIE has a mean 10 nm bandwidth. 
Assuming a uniform sampling over the useful range of the HSIE, incorporating this 10 nm 
bandwith of the illumination into the model yields some interesting results, shown in Figure 55. 
 
 
Figure 55: 10um scatters, with a 10 nm illumination bandwidth and uniform sampling of the spectra 
 
 
In essence, the wide 10nm bandwidth of the light is smoothing out the scattering signal that we 
are looking for, and then sub-sampling it. Scattered signals are not as intense as the original light, 
and so to increase the power of the observed signal, it is possible to select an angle for which the 
 85
reflected signal would be strong for which both signatures were somewhat orthogonal (to 
maximize the distance between the classifiers).  and  examine the 
wavelength-angle topology (backscattering only) in different scales for the beads used in the 
phantoms (0.5 µm and 1.0 µm): 
Figure 56
Figure 56: Wavelength-angle topology for 0.5µm (90-180 degrees) 
Figure 57
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 Figure 57: Wavelength-angle topology for 1.0µm (90-180 degrees) 
 
Examining the above semi-log mesh plots, the oscillatory patter can be easily seen, though there 
are some interesting minima that can be found around the 2.1 k-space. It can easily be seen that 
the 180-degree (backscatter at the exact same angle of the incident light) is a very strong signal 
to many of the other angles. However, separating that signal from the incident light is very 
difficult. The HSIE operates around 174 degrees, which is not necessarily the ideal angle. By 
way of analysis, calculating the power in each signal as well as their autocorrelation for each 
angle yields to following results shown in Figure 58: 
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Figure 58: Power and autocorrelation vs. angle 
  
The angle that the HSIE currently operates at is denoted by the dashed, vertical line. The upper 
plot shows how much power is in the reflected signals and the lower plot show the correlation 
between the signals. It can be observed that the current angle does not fair well in the power 
region and the signals being detected have a high correlation. As such, it will make 
distinguishing them more difficult. Figure 59 is a plot of the actual spectral signals found at the 
173 degree angle. 
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 Figure 59: Signature comparison at 173 degrees 
 
From a detection point of view, the signals have roughly comparable power while still being 
different from each other.  Finally, it should be noted that the observed topologies differ greatly 
depending on the bead size.  
 Comparing the observed data with model predictions is another way to verify the model 
results. Using the HSIE data collected in the previous sections, the parameters of the observed 
data were used to predict what kind of signal the HSIE should be detecting in the given case. 
After performing the same polynomial fit, the resulting signals are directly compared in the 
following figure. 
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 Figure 60: Model prediction vs. real data comparison 
 
 
The above Figure 60 contains six traces for each plot. The three red (solid lines) traces are the 
observed data, and the three green (dotted lines) are the model predictions over the field of view 
(the three boxes shown in the various plots from the model sections). There is some variance 
over the field of view, primarily in the red-light region. However, overall, the signal changes 
little over the field of view of the model is small, and so it is reasonable to allow subsequent 
analyses to ignore a given pixel’s position in the imaging view, thus treating each pixel as an 
independent sample.  
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Looking at the top plot (0.5 µm bead comparison), there is a rough correlation of the 
oscillatory structure between the model and the observed. Some peaks are shifted slightly but 
others match. From a frequency-domain perspective, there are two (2) complete cycles.  
Looking at the bottom plot, the signal that had the best correlation with the (nominal) 
“1.0um beads” was in fact the predicted curve for 1.03 µm. This discrepancy between the 
prediction and the observed bead size is within the ±3% variance in size distribution listed for the 
beads used in the phantom. From a frequency domain perspective, there are four (4) complete 
cycles in the observed data, but four and a half (4.5) cycles in the model’s curves. 
It is interesting to note that as the signal shifts from the blue to the red part of the 
spectrum, the correlation shifts as well. The reason for this could be from a prism-like effect of 
the cuvette wall.  
For , the media and bead refractive indices are 1.33 (water) and 1.59 (polystyrene 
bead manufacturer’s value) respectively. It should be noted that other values for the refractive 
indices (±0.05) of the media and beads can be chosen such that the green curves can be made to 
better overlap the red traces. However, improving the overlap for one bead radius makes the 
other radius traces overlap much less. This also serves as a reminder of the sensitivity of the 
scattering signal to the indices of refraction.  
Figure 60
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4.4 CLINICAL WORK 
 
The first clinical trial was located at the University of Pittsburgh Medical Center (UPMC). Dr. 
Neil Christie and his staff aided in this by providing the opportunity to work in conjunction with 
another study to collect in vivo data using the HSIE in the operating room (see Figure 61).  
 
 
Figure 61: Dr. Christie and his group using the HSIE in the operating room 
 
Over the span of almost 1 year, data was obtained from 30 patients. The following table 
summarizes the patients who participated, from whom data was acquired successfully. 
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Table 4: Patient racial and gender breakdown 
 Asian Black Caucasian Totals 
Male 0 0 15 15 
Female 0 1 14 15 
Totals 0 1 29 30 
 
 
Among the issues that encountered while taking data from live patients were: 
• Motion artifacts. One quarter of a second was faster than any other spectral data collector 
found in the literature, but it was still not fast enough. Tissue movement from the nearby 
heart presented band-to-band motion artifacts that had to be accounted for.  
• Triggering issues. Instead of relying solely on the operator/surgeon to trigger the data 
collection at the ideal time, using a semi-automatic trigger yielded superior results. This 
semi-automatic trigger took the form of allowing the system to wait for up to 3 seconds 
until images with a good signal-to-noise ratio were in view before starting the scan. 
Empirically, that limited the system to 170/256 and 240/256 of the camera’s intensity 
range and gave reliable results with only a few over-exposed or under-exposed images in 
extreme cases of movement. 
• Specular reflection. Given the small angles involved, intense specular reflection from 
surface in-homogeneities would occasionally burn-through the polarizers and over-
expose pixels. 
• Display artifacts. The Windows operating system used by the data collection and display 
computer only supports 8-bit grayscale images. Coupled with the contrast limited of LCD 
screens, this made eyeball estimates on the pixel intensities in a given 12-bit image very 
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unreliable. Mathematical metrics were quickly derived and implemented in the software; 
eye estimates were limited to making only the most general qualitative assessments. 
• Tissue trauma. Passage of the endoscope into the lung traumatizes the tissues, causing 
inflammation and bleeding in some cases. In this study, patients were placed only under a 
light sedation, and so in some cases, coughing/lung clearing reflexes were not suppressed 
sufficiently and would be inadvertently triggered. Such coughing usually traumatized the 
airways enough so that blood would begin to flow down and coat the visible tissues. This 
blood coating would make it impossible to optically biopsy the underlying tissues, and so 
often it was a race against time to image the tissue before it became impossible.  
Unfortunately (from a scientific viewpoint), data could not be collected from a patient that turned 
out to be positive for lung cancer. This raises a few questions about the sensitivity and accuracy 
of the sputum test used for screening patients, as well as makes estimating the sensitivity and 
specificity of the HSIE for this application impossible. 
With regards to software-related issues, motion artifacts for in vivo imaging of tissue 
proved to be very problematic. Unintentional movement by the target and/or the surgeon holding 
the endoscope made it very difficult to capture spectral-cubes of with good pixel signal-to-noise 
ratios (SNR) without over or under exposing the image—particularly in the lungs near moving 
organs like the heart. This issue is partially related to the Windows operating system’s inability 
to display intensity gray-maps at depths greater than 8 bits-per-pixel (our camera captures at 12 
bits-per-pixel). The conversion algorithms available to us have a tendency to make the operator 
think that the image is over-exposed, when in fact it is far from it. Furthermore, it is difficult for 
the operator to trigger acquisition before the ideal frame is in view. Consequently, an automatic 
pixel intensity range checker was implemented in the software that would cause the spectrum 
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acquisition to be delayed until the pixel-intensities were within a user-definable range. This 
automatic feature was very successful in giving us consistent pixel SNR and dramatically 
reducing the number of spectral-scans required in order to get a “good” one. However, while this 
did reduce the impact of inadvertent movement of the scope and/or tissue target, it did not 
eliminate it. It is estimated that a camera speed-up by at least a factor of 3 will be necessary to 
minimize motion smear sufficiently for it to cease to be a concern. 
 We have recently undertaken a second study, planning it based on some of the lessons 
learned in the research described above. This study is still in progress at the Allehgheny general 
Hospital in Pittsburgh PA, using a more recent version of our HSIE instrument. One of the new 
goals in this study was to aid the surgeon by having the spectral scattering imagery guide (in 
part) some of the biopsies, with the intent to link the intrasurgical imagery with subsequent 
pathology analysis. While the technology appeared to work quite well (and reliably), and we 
were able to investigate 21 consenting patients so far, the frequent changes of participating 
surgeons, support personnel losses, and other administrative issues made it difficult to achieve all 
our goals so far. With the promised enhancements in the Pathology department’s participation in 
the analysis of the biopsied specimens, we hope to obtain more clinically meaningful results 
soon. Additional, advanced image analysis in collaboration with a group at Carnegie Mellon 
University Robotics Institute should also improve our ability to extract meaningful conclusions 
from this study. 
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 Figure 62: Same bronchoscopic biopsy-derived tissue sample imaged in three modes (Hematoxylin-eosin 
stained pathology slide, imaged directly in transmitted light; Hyper-spectral segmentation/classification of the 
same slide, based on a microscopically acquired image cube and auto-fluorescence image of the same area, 
excited at 390nm and detected at 430 
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 5.0 SUMMARY AND FUTURE WORK 
 
 
The following sections summarize the results, and propose designs for future work.  
 
 
5.1 SUMMARY 
 
This project had three major thrusts: construction of the hyperspectral imaging instrument, the 
computer modeling, and testing against phantoms. The construction of the machine was 
accomplished after the clearing of a couple of engineering hurdles. The first hurdle was the 
construction of the custom fiber endoscope, which was solved by hiring a sub-contractor to 
manufacture it. The second hurdle was the synchronized acquisition of the band-sequential 
images at high speeds. This was solved by building specialized electronics in-house that slave 
the band-sequential illumination source to a high frame rate camera, and the development of 
custom data-collection software to run on a laptop. The computer model was done by the 
translation of verified Mie calculation code from Fortran to Matlab and then performing ray-
trace calculations according to the machine geometry to predict what the image should look like. 
The last thrust, the testing against known phantoms, encountered some difficulties. The 
phantoms were built and verified by microscopic dissection and laser goniometry, but signal-to-
noise issues stemming from the unfavorable illumination angle of the tip and blurring from the 
wide bandwidth of the illumination source used made extracting the signal from the noise almost 
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impossible. The HSIE was also used to gather data in the operating room, with the intention of 
empirically comparing cancerous sites with non-cancerous sites. Unfortunately, of the 30 
patients seen, none were positive for cancer, making the empirical comparison impossible. Given 
the difficulties and additional control parameters unearthed during this project, the current HSIE 
system proved inadequate to do the task it was developed for. It is not, however, a complete 
failure. This project has pointed the way towards a device that can perform this task, but the 
existing design will need to be significantly modified in several ways as described below 
 
 
5.2 NEXT GENERATION SYSTEM 
 
The next generation HSIE system will need to have improvements made in several areas, some 
of which are simply upgrading to newer versions of the same technologies. Newer cameras with 
greater quantum efficiency, higher image acquisition rates, and better response in the 700-800nm 
(red light) spectrum range are just coming onto the market, and they could be incorporated into 
any new design. However, there are some trade-offs to be made based on the system parameters 
that have been identified as part of this work. Based on the trade-offs for these parameters, three 
new designs can be envisioned.  
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5.2.1 Next Generation System Parameters 
 
The Mie-theory based modeling has made clear several parameters will need to be estimated 
and/or adjusted to improve the strength of the desired signal: 
• Distance estimation ability: The distance from the tip to the target significantly affects the 
observed back-scattered angle. 
• Reduced bandwidth of illumination: The merging (smearing) of the signal by a broad 
illumination is destroying the signal oscillations, reducing the system’s sensitivity. 
• Minimization of systemic registration issues: It is (currently) technically infeasible for a 
fiber with two imaging bundles to be placed so that there is a zero rotational error in the 
camera’s viewfinder 
Additionally, the clinical trials with live patients have made clear some additional issues (which 
are inter-related): 
• Increased light collection/camera efficiency: Insufficient light delivery through the 
illumination fiber forces pixel binning and slower imaging rates.  
• Increased acquisition speed: Cardiac movement introduces significant motion artifacts 
(between spectral bands) into the spectral cube. 
• Specular reflection rejection (by increasing the back-scattering angle) or increased 
camera dynamic range 
• Fiber rigidity and/or diameter needs to be reduced if some of the more unusual, but still 
normal, lung lobe configurations occasionally encountered are to be explored.  
In all the designs which follow, this dissertation will explore some of the design changes that 
could be done to the distal end of the HSIE system. In all the designs, the monochromator is 
replaced with either an Acousto-Optical Tunable Filter (AOTF) or a liquid-crystal filtered light 
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source. This change is independent of tip improvements and would immediately narrow the 
illumination bandwidth from 10-12nm to approximately 2-3nm, allowing for a more finely 
sampled spectra. 
 
5.2.2 New Design #1 
 
The goal of this design is to maximize the optical angle between the light source and the imaging 
bundle, but it has the secondary effect of removing the systematic registration problem. 
Referring to Figure 63, it differs from the current HSIE design in three distinct ways. First, it 
only has one imaging bundle. Second, the illumination fiber is replaced by a more expensive 
polarization-compensated fiber that does not have a polarizer in front of it. This allows the 
illumination to be polarization-sequenced, allowing for both polarizations to be obtained through 
the single imaging bundle. Third, a method for determining the distance from the tip to the target 
is added. This is done by adding a smaller, single-mode (monochromatic) illumination fiber 
located in the center of the triangle. While data is being collected, periodically the single-mode 
fiber will be illuminated, causing a spot to appear in the image. The size of the spot will be 
inversely proportional to the distance, and thus give an approximate distance from the tip to the 
target. Increasing the scattering angle will hopefully increase the signal intensity, as predicted by 
the Mie simulation model. This fiber design should also be more flexible, as the fiber will be less 
crowded. A trade-off here is that the acquisition time will be half the rate design #1, since two 
pictures must be taken to capture both parallel and perpendicular information. In this design the 
illumination fiber is replaced by a more expensive dispersion compensated fiber that does not 
have a polarizer in front of it, and only one imaging fiber bundle is used (that does have a 
polarizer). This change would allow the illumination light source to be rapidly polarized (using a 
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Pockels cell, for example), thus it then becomes possible to collect both the parallel and 
perpendicular light using the same imaging fiber. 
  
 
Figure 63: New Fiber design #1 
 
 
This design will maximize the geometric angle between the illumination and imaging bundles. 
However, the angle gains are modest given the 2mm constraint and a 10mm working distance. 
Shortening the working distance would allow the illumination fiber to be polished in a non-flat 
manner at a 10 degree angle, artificially enhancing the incident light level. 
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5.2.3 New Design #2 
 
The fiber polishing approach does not work in the case of two imaging bundles, and so to 
increase the angle in this case one must make the total diameter larger. Hence, new design #2 
(shown in Figure 64) assumes that the diameter is allowed to be expanded to 3mm. Furthermore, 
it extends the current design in two distinct ways. First, the illumination fiber is replaced by a 
more expensive dispersion compensated fiber that does not have a polarizer in front of it (as in 
the first design). This allows flexibility in how one uses the two fiber imaging fiber bundles. One 
could use it in the manner of the original HSIE, mimicking the original polarizer configuration 
and collecting both images simultaneously. One could also sequence the illumination 
polarization and only collect data from one imaging bundle. In this configuration, the unused 
bundle could be optically diverted to another use such as an RGB brightfield camera. If the 
illumination spectrum is similar to the RGB spectrum, the RGB camera could collect light at the 
same time the other spectral information is collected. Furthermore, the light-sources could be 
interchanged, allowing a broad-spectrum illumination to instead be used with the RGB when 
spectral data is not being collected. Secondly, the range-determination scheme described in the 
first design is also included in this design.  
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 Figure 64: New Fiber design #2 
 
This design would solve many of the problems outlined above, but does not address the systemic 
registration issues unless data is collected using only one of the imaging bundles. However, the 
fact that data can be collected in several modes makes this design flexible for research purposes.  
 
 103
5.2.4 New Design #3 
 
If cost and endoscope diameter were no restrictions, it would be desirable to dispense with the 
imaging fibers all together and instead switch to a camera-on-the-tip design (see Figure 65). 
Such a radical design change would accomplish several things. 
  
 
Figure 65: New fiber/endoscope design #3 
 
 
First, the registration issues between the parallel and perpendicular images would be greatly 
simplified (only one axis of freedom and no rotation adjustment). Second, increased light from 
the imaged tissue would reach the camera. Third, the alternate (lower) illumination fiber could be 
used for either other imaging modalities (such as fluorescence lifetime imaging, whose required 
excitation laser intensity would burn through any film polarizer) or as an alternate light source 
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that would allow even more detailed analysis of the distance to the surface being imaged than the 
six rangefinders would allow. Fourth, this tip would allow the rest of the endoscope to be much 
more flexible because of the omission of the fiber bundles. Fifth, the inclusion of several optical 
rangefinders would improve the range estimation for multiple quadrants of the image, providing 
for a more robust analysis of the surface being imaged.  
 
In conclusion, for the application of Mie theory to become a powerful intra-surgical method 
using no contrast agents, the following is needed: 
• A fundamental understanding of what Mie scattering regime light-tissue interaction is 
yielding 
• Carefully designed and implemented technologies 
• Moving from a point spectroscopy to a full-fledged imaging modality, to be on par with 
established endoscopy techniques and current minimally invasive surgical practice 
This work show the first steps in the development of this powerful method. Mathematical 
modeling and tissue phantoms aid in understanding the fundamentals. Realization of the 
prototype HSIE and its subsequent use in a real operating room aids in understanding where the 
state of the technology is today, and what design, logistic and performance issues need to be 
addressed. It also aids in understanding how new methodologies can be added to the established 
endoscopy procedures, and how HSIE can help with optical biopsy, and, more generally, with 
the overall goal of better diagnostics, more tightly coupled - spatially and temporally - into 
treatments. 
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 Figure 66: Bench-to-bedside translational continuum  
 
In the often mentioned bench-to-bedside translational continuum (within which this project tries 
to move from the dotted-red arrow to the solid-red arrow), the first implementation of the HSIE 
glided when pushed out of the laboratory nest. I am confident that the next incarnation will fly, 
rather than just glide.       
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APPENDIX A 
 
 
 
 
CIRCUIT DIAGRAM AND PROTOCOL OF SEQUENCER 
 
 
 
 
The diagram which follows is a functional schematic of the sequencer described in the previous sections. The 
software protocol which controls it then follows. 
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Overview of Sequencer Protocol 
 
The Line Protocol is a frame-based canonical byte-encoded protocol. Commands consist of an 
operator (OP), followed by up to six (6) bytes of data, followed by a checksum (CS) byte, 
followed by a carriage return (#13): 
 
Operator 
(OP) 
Data Byte 0 – Data Byte 6 
(D0 – D6) 
Checksum  
(CS) 
End of Frame 
(#13) 
 
The checksum is a running total of all previous bytes, excluding itself and the end-of-frame byte. 
The maximum length of the frame (in bytes) is 9. However, for maximum compatibility, all 
bytes of the frame except the End-Of-Frame (#13) will be encoded in hex. Therefore, the 
maximum length possible of a hex-encoded frame is 17 characters. For example, a frame of 
(#10,#11,#00,#21) with the End-of-Frame excluded would be encoded as 0x0A0B0015. 
Consequently, all communications will be in canonical lines of hex digits. Command Frames can 
have up to 8 data bytes, while Response frames can have up to 48 data bytes. 
 
Operator 
 
The operator is broken up into two parts: the most significant 4 bits and the least significant four 
bits -- In other words, two hex digits. The first hex digit is the Operator Group (OG), and the 
second digit is the actual command or response message.  
The following operators (commands and responses) are currently defined (all numbers are in 
Hexadecimal code): 
Group 0: Generic Acknowledgements 
 
00: Bad Frame (Checksum failed) 
01: Unrecognized Command 
02: Invalid Data (but valid command) 
03: Overflow 
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07: Power-on/reset flag set 
08: Change Acknowledged 
0C: Unsigned integer response (more to 
follow) 
0D: Unsigned integer response (final) 
0E: String response (more to follow, 
concatenate) 
0F: String response (final) 
Group 1: Device Information 10: Get Device ID String 
11: Get Device Serial Number 
Group 2: Status Information 20: Get power on, self test hardware error 
code 
21: Get power on, self test software error code
22: Get configuration error code 
23: Get current state 
24: Get pass count 
Group 3: Device programmable 
options 
30: Clear Power-Reset flag  
31: Get Operating Mode 
32: Set Operating Mode 
Group 5: External Trigger port 50: Get Trigger states 
52-58: Get Trigger #0-#6 Mode 
59-5F: Set Trigger #0-#6 Mode 
Group 4: Voltage Sequencer #0 40: Initialize Sequencer to known zero state 
41: Get Mode 
42: Set Mode 
43: Get Tail 
44: Set Tail  
45: Get Slot (#) 
46: Set Slot (#, value) 
47: Get Active Slot 
48: Set Active Slot (#) 
49: Get Trigger Control Mode 
4A: Set Trigger Control Mode 
4E: Get Info  
4F: Get Secondary Info 
 
 
Error Codes 
Currently defined error codes are: 
Hardware 00: No Error 
Software 00: No Error 
Configuration 00: No Error 
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Operating Modes 
Currently defined operating modes are: 
00 Suspended Operation 
01 Programming mode 
02 Single Pass 
03 Repeating Pass 
 
Operating States 
Currently defined operating modes are: 
0x Suspended Operation 
1x Programming mode 
2x Start of Pass 
3x Repeating Pass 
Where x=software specific sub-phase. Note that the first hex digit corresponds to the operating 
mode. 
 
Examples 
 
There are some example protocol exchanges to help in understanding the protocol. Note that 
after a power up, the box will send only a 0x03 response to any command it receives until the 
power-on reset flag command (0x30) is received. This allows the controlling computer (master) 
to detect the event and react appropriately. 
 
Power-up example 
 
Master Device Comment 
(Anything but command 30)   
 (07)  
30.  Clear power-on flag 
 08.  
All numbers are in hex. 
 
A basic startup information query example 
 
Master Device Comment 
10  Get Device ID String 
 0F + String Reply 
11  Get Serial Number 
 0D + number Reply 
20  Get Hardware error code 
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 0D + number Reply 
21  Get Software error code 
 0D + number Reply 
22  Get Config error code 
 0D + number Reply 
31  Get Current Mode 
 0D + number Reply 
23  Get Current State 
 0D + number Reply 
All numbers are in hex. 
 
Reading the current sequence from the box 
Master Device Comment 
F2  Request the entire list 
 0C + number Slot #1 
 0C + number Slot #2 
 0C + number Slot #(n-1) 
 0D + number Slot #n 
All numbers are in hex. 
 
Changing the current operating mode of the box 
Master Device Comment 
32.02  Select suspended operation 
 08 Okay 
All numbers are in hex 
Programming a fresh sequence into the box 
Master Device Comment 
F4  Clear the list 
 0D + number Number of slots remaining (okay) 
F3 + 16-bit 
number 
 Add first number 
 0D + number Number of slots remaining (okay) 
F3 + 16-bit 
number 
 Add second number 
 0D + number Number of slots remaining (okay) 
F3 + 16-bit 
number 
 (Repeat as necessary) 
 0D + number Number of slots remaining (okay) 
All numbers are in hex 
If the capacity of the box is exceeded, it will respond with “03 - Overflow” 
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Line Coding Examples 
 
Frame (in bytes, hex 
digits) 
Line coding (in 
characters) 
Symantec Meaning (decimal numbers)
30. 3030¶ Clear Power on reset 
32.01. 320133¶ Set operating mode to 1 
 ¶  
0C.2D. 0C2D39¶ 45 (more to follow) 
0D.2D. 0C2D3A¶ 45 (final number) 
0E. ¶ “AOTF SEQ” (more to follow) 
0F. ¶ “UENCER” (final) 
 
Programming a fresh sequence into the box 
Master Device Comment 
F4  Clear the list 
 0D + number Number of slots remaining (okay) 
F3 + 16-bit 
number 
 Add first number 
 0D + number Number of slots remaining (okay) 
F3 + 16-bit 
number 
 Add second number 
 0D + number Number of slots remaining (okay) 
F3 + 16-bit 
number 
 (Repeat as necessary) 
 0D + number Number of slots remaining (okay) 
22  Get Config error code 
 0D + number Reply 
31  Get Current Mode 
 0D + number Reply 
23  Get Current State 
 0D + number Reply 
All numbers are in hex. 
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APPENDIX B 
 
 
 
 
INTERNAL REVIEW BOARD (IRB) DOCUMENT 
 
 
 
Imaging Elastic Scattering Spectroscopy Endoscopy IRB Protocol 
 
Lung Fluorescence Endoscopic Surveillance in Patients at High Risk For 
Developing Lung Cancer 
 
RESEARCH PROTOCOL ABSTRACT: The purpose of this study is to evaluate the efficacy 
and usefulness of the LIFE-Lung Bronchoscopy to identify early molecular markers that 
correlate with pre-cancerous carcinoma in situ (CIS) or micro-invasive lesions and eventually 
will be used to direct their identification and treatment. Patients with non-small cell lung 
carcinoma (NSCLC) that have undergone surgical lung resection, patients with head and neck 
squamous cell carcinoma (HNSCC) that have undergone radical head and/or neck dissection and 
patients with severe chronic pulmonary disease will be recruited. Approximately 250 patients 
will be enrolled in this study through the University of Pittsburgh Cancer Institute. 
 
HYPOTHESIS AND SPECIFIC AIMS:  
• Establish a surveillance bronchoscopy program for early detection of NSCLC patients, HNSCC 
patients, and patients with limited pulmonary reserve, who are at a high risk for developing 
NSCLC. 
• Study differences in the mutations in p53 and K-ras genes, bombesian-like receptor-subtypes 
and HGF protein levels in normal mucosa, metaplasia, dysplasia and CIS.     
• Monitor the histologic and molecular impact of PDT on high grade dysplasia and CIS. 
• Monitor the impact of Imaging Elastic Scattering Spectroscopy (IESS) on detecting dysplasia 
and CIS. 
 
BACKGROUND INFORMATION AND SIGNIFICANCE: The development of carcinoma 
of the lung follows a latent period that spans several decades as the normal respiratory 
epithelium is exposed to various carcinogens.  The response of the normal mucosa to these 
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stresses is believed to be a predictable progression from high grade dysplasia to carcinoma in situ 
and eventually resulting in invasive carcinoma.(1) There is an average period of four to five 
years during which time individuals exfoliate markedly atypical cells (that actually represent 
carcinoma in situ) into the bronchial secretions before the progression to an invasive 
carcinoma.(2)  
 
If these pre-invasive (high grade dysplasia and carcinoma in situ, CIS) lesions can be detected more efficiently with 
the LIFE-lung Fluorescence Endoscopic System it will then be possible to interrupt and/or reverse the process of 
carcinogenesis with a new, FDA approved, non-invasive therapy, i.e. Photodynamic Therapy (PDT).  
 
PDT has been used investigationally for NSCLC since 1980. A prospective phase II study on 
PDT with Photophrin II for centrally located early stage NSCLCs by the Japan Lung Cancer 
Photodynamic Therapy Group demonstrated an 85% CR in 54 patients with 64 carcinomas after 
initial PDT therapy with a mean duration of complete response of over 14 months. (3) More 
recently, (1997); Cortese et. al. from the Mayo Clinic documented a complete response in 15/21 
patients (16/23 cancers) after an initial PDT session. Subsequent primary lung carcinoma 
developed in 5/21 patients (24%), however 9 patients (43%) were spared an operation after a 
mean follow-up of 68 months. (4) On January 9, 1998 Photodynamic Therapy with the 
photosensitizer Photophrin II, using a 630 mm laser was approved for T1 NSCLCs.(3) 
 
Dysplasia and carcinoma in situ are approximately 90% curable with PDT. At present, less than 
15 % of patients with invasive lung cancer can be cured even with aggressive, multimodality 
treatment strategies (surgery, chemotherapy and/or radiation therapy).(5)  By the time an 
invasive carcinoma of the lung produces symptoms, it is usually locally or systemically advanced 
beyond curability. In 1998, only one out of eight people diagnosed with invasive, non-small cell 
lung carcinoma (NSCLC) will live five years.   
 
At present, occult lung carcinomas in these high-risk patients are most commonly identified 
through periodic sputum cytology and/or standard routine chest x-rays. Both of these modalities 
are less than optimum screening tools -- the former does not localize the lesion within the 
tracheobronchial tree and the latter is neither sensitive nor specific for malignancy. Screening 
with LIFE bronchoscopy yields a 170 - 500% improvement in the detection of high-grade 
dysplasia and CIS than standard light bronchoscopy however the expense of such aggressive 
screening can only be justified if the incidence of cancer in the screened population is high. Two 
populations of high risk patients are the focus of this study: those with severe chronic obstructive 
pulmonary disorders as demonstrated by obstructive pulmonary functions tests and those who are 
status-post resection of a NSCLC with no current evidence of disease. 
 
The North American Lung Cancer Study Group showed that Stage I (T1,N0,M0) non small cell 
lung carcinoma patients who have undergone complete surgical resection have a 60-70% five-
year survival but have a 3.6% per year risk of developing a second lung primary.(6) Data from 
the Mayo Clinic on patients that underwent surgical resection for sputum cytology positive but 
radiologically occult lung cancer found that second primary lung cancers occurred at a rate as 
high as 5% per year in this patient population.(7) In a collective review of 1406 patients with 
occult or stage I completely resected lung carcinomas, the incidence of second-primary lung 
cancers was 11.4% (range 3-30%).(8) The mortality from second-primary lung carcinomas in 
surgical patients is much higher than for the first tumor because treatment are both more limited 
 115
and complicated as a consequence of their prior lung resection.(9) Second NSCLS primaries are 
a particularly vexing treatment dilemma in patients who have undergone a prior curative, 
surgical resection because of their limited, residual pulmonary reserve.  
 
Patients with a history of Head and Neck Squamous Cell Carcinoma (HNSCC) are at a high risk of developing 
carcinomas throughout their respiratory tract, with many of these arising in the lungs. (23) Many of these tumors are 
found to be low-stage lesions and are amenable to treatment if detected early enough. (23) In a retrospective study, 
Leon et al. (24) reported 302 (16%) out of 1,845 patients with HNSCC had developed a second carcinoma, with 
31% occurring in the lungs. In support of this finding, a study done by Cahan et al. (25) demonstrated that a second 
primary lung carcinoma was present in 137/142 lung tumors in patients with HNSCC.  Occurring at a rate of 3-7% 
per year, second carcinomas may lead to significant complications and an overall poor survival rate in this particular 
group of patients. (23,24) Close medical surveillance would allow for an earlier diagnosis of a second tumor and a 
greater chance of benefiting from preventative therapy. (23,25) Cooper et al (26) believe that preventative therapy 
will have its greatest impact in those patients who continue to have routine follow up visits and who are treated for 
an early stage primary tumor. 
 
Patients with severe COPD are also at high risk for developing NSCLC and are difficult to 
manage with curative-intent because their diminished pulmonary function prohibits pulmonary 
resection or definitive irradiation. The recent revival of lung volume reduction surgery (LVRS) 
to improve the mechanics and subjective sense of dyspnea of patients with severe, disabling 
COPD has reinforced the concomitant risk of lung cancer in these patients.  A clear correlation, 
independent of cigarette smoking, exists between obstructive lung disease and lung cancer.(10) 
Hazelrigg et al.(11) reported finding18 lung carcinomas in 281 patients who underwent LVRS 
for an overall incidence of 6.4%. These data are consistent with the 7.8% incidence of 
carcinomas in this same LVRS population previously reported by Pigula et al. from our 
institution in 1996.(12) In Hazelrigg’s series, 9/19 (47.3%) of the lesions were radiographically 
occult -  4 were identified intra-operatively and 5 lesions found incidently in the resected 
specimen by the pathologist.(13)  
 
White light bronchoscopy has been shown to be a useful tool in localizing radiographically 
occult lesions.  However, Woolner et al. demonstrated that only 29% of carcinoma in situ 
(CIS)(12) and 69%(15) of micro-invasive tumors are identified by experienced bronchoscopists. 
In 1996 an endoscopic lung imaging system developed by the British Columbia Cancer Research 
Centre in conjunction with Xillix Technologies Corp., known as the LIFE-lung Fluorescence 
Endoscopy System was approved by the FDA.  LIFE-lung bronchoscopy is performed with a 
helium-cadmium laser using blue light @ 442 nm for illumination and allows visualization of 
these differences in normal and abnormal tissue autofluorescence. Lam and others have shown 
that the tissue autofluorescence spectra of areas of dysplasia and carcinoma in situ differ 
significantly from those of normal bronchial tissues. (16) Specifically, LIFE Bronchoscopy 
improved sensitivity of detection of metaplasia and dysplasia is improved by 171% over current 
WLB. LIFE bronchoscopy’s sensitivity for the detection of CIS is 500% greater than that of 
standard WLB. 
  
In vivo spectroscopy with an optical, multichannel, analyzer enables the LIFE bronchoscopy 
system to demonstrate a difference in autofluorescence intensity (predominantly in the green 
region of the visible spectrum) of areas of dysplasia or carcinoma in situ in comparison to normal 
bronchial tissue. These autofluorescence differences in the absence of exogenous drugs were 
exploited to design and develop the LIFE-lung system.(17) In a normal bronchus, most of the 
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auto-fluorescence comes from the submucosa.(18) (Most likely, the decrease in fluorescence 
intensity in dysplasia and CIS is due to both thickening of the epithelium, loss of endogenous 
fluorophors and increased light absorption by the increased capillary density in these lesions.)  
 
The LIFE-lung Fluorescence Endoscopy System is comprised of a 125 mW helium-cadmium 
laser as a source of blue light (442 nm), two image-intensified CCD cameras with green (520nm) 
and red (>630 nm) filters, a computer with an imaging board and a color video monitor.(19) The 
blue light is delivered to the bronchial surface with an adapter that connects to the fiberoptic 
light-guide of a standard, white-light, bronchoscope.  Non-collimated light at 12-15 mW is 
emitted at the distal end of the bronchoscope.  The fluorescence from the bronchial surface is 
captured by the imaging bundle of the LIFE-lung Endoscopy System.  Images of the bronchial 
mucosa at both red and green wavelengths are simultaneously captured by the image intensified 
CCD cameras onto the imaging board of the computer.  These images are then integrated using a 
specially developed algorithm such that normal tissue can be differentiated from dysplasia and 
CIS and are displayed in real time.   
 
Fluorescence bronchoscopy using the LIFE system is identical to standard flexible bronchoscopy 
except that it utilizes blue light (from a Helium-Cadmium light source) in contrast to white light 
(commonly emitted from a Xenon or Halogen light source). Both fluorescent and reflected light 
are produced when the bronchial surface is illuminated by visible light, the difference is that with 
the LIFE-lung system, the image is reconstructed from emitted fluorescent light instead of from 
light reflected  off of the bronchial surface.  Emitted fluorescence and reflective light are 
separated by appropriate filters.   
  
To compare, the standard Pentax Videobronchoscope System (VB-2000, Asahi Optical Col Ltd., 
Tokyo, Japan) uses a 300 W Xenon short-arc lamp (Model EPM-3000) with a filter wheel to 
produce red, green and blue light sequentially at a video rate.  The red, green and blue 
reflectance images are then captured sequentially by a single CCD detector at the tip of the 
bronchoscope and combined to construct a reflectance color image.  Using the Pentax light 
source the light-intensity at the tip of the bronchoscope is 200 mW in contrast to the 15-20 mW 
output from the Helium-Cadmium laser light source.  There has not been a single report of any 
adverse effects from exposure of the human bronchus to visible light since the introduction of 
fiberoptic bronchosopy in 1967. 
 
In addition to using the LIFE-Lung Fluorescence Endoscopic System, we will also be investigating the use of 
imaging spectroscopy.  In collaboration with Carnegie-Mellon University, Daniel L. Farkas, PhD and Elliot 
Wachman, PhD have proposed an alternative optical procedure in the early detection of cancer known as 
Imaging Elastic Scattering Spectropscopy (IESS).  This technique is sensitive to small changes in tissue 
morphology, and thus provides a way of detecting abnormal lesions in vivo in much the same way that a 
pathologist routinely does ex vivo.   This system performs imaging spectroscopy, in which measurements are 
made over 10,000 points at once.   The intent of this procedure is to collect spectroscopic image data from 
abnormal tissue detected on the LIFE system.  The IESS scope will be inserted through the instrument 
channel of the LIFE endoscope prior to any biopsies being taken and the image will be acquired within 0.5 
seconds.  The IESS scope is then removed and the biopsy performed as usual.  The IESS data will be 
analyzed, correlated with the pathology reports and stored at Carnegie-Mellon University under the 
supervision of Dr. Elliot Wachman, PhD.  At the conclusion of the trial, the complete set of spectroscopic 
images will be categorized by lesion type and evaluated for sensitivity and selectivity.    
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This IESS scope is manufactured, as specified by Drs. Farkas and Wachman,  by Instrument 
Technologies, Inc., a nationally recognized producer of custom OEM medical products in full 
compliance with the FDA’s GMP and ISO 9001 regulations.  The light source to which this 
scope is connected (TILL Photonics, Model Polychrome IV) is based on a 150W Xenon lamp, 
similar to that used in conventional endoscope light sources.  A standard digital camera mounted 
to the endoscope and PC complete the IESS system. 
 
SIGNIFICANCE: The risk of developing second lung primary in a patient with NSCLC who has 
undergone a potentially curative resection is almost 5% per year with limited salvage treatment 
options available (20).  Identification of pre-malignant changes such as high-grade dysplasia and 
carcinoma in situ has been elusive until the development of the LIFE-Lung Fluorescence 
Endoscopic System which received FDA approval for the detection of dysplasia and CIS in 
1996. Unpublished data from a recent multi-institutional clinical study showed that LIFE 
bronchoscopy, when used as an adjunct to conventional WLB, improved the physician’s ability 
to identify moderate/severe dysplasia or worse, when compared to WLB alone on a per-patient 
basis from 37% to 75% and on a per-lesion basis, detection improved from 25% to 67%; and an 
overall 171% increase in the detection rate (21). 
 
Historically, areas of high-grade dysplasia and carcinoma in situ could only be “followed” 
however, significant data now exist that suggest that these early lesions are 90% curable 
employing a noninvasive, local treatment i.e. PDT (22).  The LIFE-Lung system can be used to 
correlate the histopathologic changes in the tracheobronchial epithelium with molecular 
abnormalities at a given point is time (static), to study their progression longitudinally over time 
(dynamic) and to monitor their response to therapeutic intervention with photodynamic therapy.  
Identification of early activation events in the mucosa could translate into means to perform 
molecular screening of sputum as an adjunct to cytologic screening. 
 
 
PROGRESS REPORT AND PRELIMINARY STUDIES: (See Background section). 
 
 
RESEARCH DESIGN AND METHODS: Two hundred and fifty adult (age>18) male or 
female patients from three different high risk patient populations will be studied. The first 
population consists of patients with Non-Small-Cell Lung Carcinoma (NSCLC) who are status 
post complete resection and have no evidence of disease (NED). The second group is composed 
of patients with Head and Neck Squamous Cell Carcinoma who are status post radical head 
and/or neck dissection and are NED.  The third population of patients are those with severe 
chronic, obstructive, pulmonary disease (COPD).  These three cohorts of patients were selected 
because of the high incidence of CIS development in each group, not for comparative purposes 
between the populations.  No patients will be excluded on the basis of race, gender, or HIV 
status.  
 
Bronchoscopic Procedures: 
The bronchoscopies will be done in the Department of Thoracic Surgery at UPMC.  All 
investigators will be checked for color blindness using standard color charts.  Study patients will 
be NPO for a minimum of six hours prior to the procedure and one hour afterwards.  Standard 
preoperative parenteral medications are permissible.  Lidocaine Lolipop, Lidocaine Injection 
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(LTA), Preoperative and intraoperative Versed and Fentanyl, intraoperative 1% Topical 
Xylocaine (vocal cord and tracheobronchial paralysis). Viscous Lidocaine (hypopharynx), 
Cetacaine spray (nasopharynx) and Intra-tracheal instillation of 1% Lidocaine (vocal cords) will 
be used to achieve adequate airway anesthesia.  Conventional WLB will be carried out first using 
an Olympus BF20D fiberoptic bronchoscope.  The entire tracheobronchial tree will be inspected 
and videotaped. The exact location of any Class II and Class III changes will be recorded in the 
image management program in the LIFE system during the bronchoscopy.  Tissue will be 
classified according to the following: 
Class I: no visual abnormalities, appears normal. 
Class II: inflammation, trauma, anatomical anomalies, possible metaplasia. 
Class III: changes suggestive of moderate or severe dysplasia, carcinoma in situ, invasive cancer. 
 
During the WLB exam the physician will be allowed to change classifications for a given site.  
However once fluorescence bronchoscopy has begun the physician will not be allowed to make 
revisions to the classifications made during the white-light exam. 
 
Fluorescence bronchoscopy will be performed using the LIFE-Lung Endoscopic System 
following completion of the WLB examination, by merely changing light sources.  Again, the 
entire exam is to be videotaped and narrated.  The precise location of all Class II and Class III 
changes will be recorded in the image management program of the LIFE system.   
 
Tissue samples will be classified according to the following categories: 
 
All Class II and Class III lesions will be biopsied with forceps, at least one biopsy per area.  In 
addition, one random biopsy will be obtained from a visually (by WL and LIFE bronchoscopy) 
Class I area.  A total of four random biopsies will be taken if no Class II or Class III areas 
identified by WLB or LIFE bronchoscopy.  
   
All biopsies will be snap-frozen (for molecular markers), formalin-fixed and paraffin embedded 
for hematoxylin and eosin staining. 
 
Interpretation of the histopathology will be made by one designated pathologist, Samuel 
Yousem, MD, without knowledge of the LIFE-bronchoscopic findings. 
 
No radiation or photosensitizing agents will be administered to patients for either the WLB or 
LIFE-bronchoscopy exams. 
 
Molecular Markers: 
In addition to the tissue samples a blood sample (one 10 ml green top tube) will be taken.  
Patients will also be asked to fill out a questionnaire about smoking history, family history, and 
other risk factors, as well as place of residence and other demographic information. The patients 
will not receive results of the research for molecular markers and they will not be placed in the 
patients medical record. 
 
1-2 mm3 biopsies will be taken.  A matching normal biopsy will be taken for each biopsy of a 
lesion.  These will be designated by a alphanumeric code to designate anatomical location and 
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patient ID.  One biopsy from each area will also be taken for histology (formalin fixation).  The 
other biopsies will be snap frozen in liquid nitrogen in the OR. within 30 seconds of collection 
and transported on dry ice or in liquid nitrogen to Dr. Siegfried's laboratory, where they will be 
stored at -80o C until distributed to investigators.  A portion of the biopsy will be fresh frozen 
and analyzed for DNA mutations in p53 and K-ras genes. 
 
The following preparations from the biopsies will be made. Each abnormal biopsy and matching 
normal biopsy will be used for either DNA, RNA, or protein isolation.  An attempt will be made 
to distribute the biopsies equally among the three procedures.  From the isolated DNA, mutations 
in the p53 gene and the K-ras gene will be assayed. Researchers have shown that p53 and K-ras 
deletions occur in lung tumors.  Preliminary data suggest that bombesin-like peptide receptors 
are over-expressed in smokers, therefore these receptors will be assayed by reverse transcriptase- 
polymerase chain reaction (RT-PCR).  From the isolated protein, telomerase activity will be 
determined using the TRAP assay, and levels of HGF protein, believed to be associated with the 
invasive process in lung cancer, will be assayed by Western Blot.  The goal of these studies is to 
identify molecular markers that could distinguish between normal mucosa, metaplasia, dysplasia 
and carcinoma in situ.  The effect of PDT on any/all markers identified will also be studied. 
 
The blood will be treated as follows: white blood cells will be separated by Ficoll-Hypaque and 
frozen at -80o C for later DNA isolation.  The plasma will be stored frozen in 2 ml aliquots in a 
non-frost free freezer.  The white blood cells will be used for isolation of DNA to determine 
cytochrome P450 (CYP) genotypes and Phase 11 enzyme genotypes.  Although there are no 
immediate plans to assay any markers in the plasma, it will be retained for future use.  Sputum 
specimens will be analyzed for the following molecular markers:  Kras and p53 mutations as 
well as hepatocyte growth factor. 
 
The bloodwork, sputum and biopsy specimens will be under the control of the principal 
investigator of this research project and will not be shared with secondary investigators (i.e., 
other than those involved in the current research project).  The results of these tests cannot yet be 
interpreted or applied in a clinically relevant or meaningful manner and will not be provided to 
the subjects.  If this information should become clinically relevant as a result of the availability 
of new strategies for the prevention or treatment of lung cancer it will be provided to the patients. 
 
We anticipate that up to 350 patients per year will be asked to participate. We expect 
approximately a 50% accrual rate, however, only about 50 to100 will actually have lesions that 
require biopsy, who will contribute tissue to the study.  About 75% are estimated to come from 
the previous lung cancer group and 25% from the COPD population.  Individuals who have high 
grade dysplasia, carcinoma in situ, or microinvasive carcinoma will be offered photodynamic 
therapy.  We will obtain serial biopsies from these patients for clinical surveillance annually in 
patients with normal mucosa and at six months for patients with metaplasia or dysplasia. 
 
Photodynamic Therapy for High Grade Dysplasia and Carcinoma In Situ Lesions: 
Photodynamic therapy for early (T1) NSCLC lesions was approved by the FDA on January 9, 
1998. PDT for high grade dysplasia, carcinoma in situ, or invasive carcinomas (T1 lesions) will 
be administered in the standard well-published fashion. Specifically, a total dose of 100-200 
J/cm2 will be delivered using a KYP/YAG-dye tuned to emit a 630 nm wavelength light 48 hours 
after a Photofrin II injection (2mg/Kg), to those lesions over approximately 500 seconds. A 1cm 
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or 2.5 cm cylindrical diffuser fiber - the length dependent upon the axial length of the lesion will 
be used. A clean-up bronchoscopy (white light) is performed to remove mucous and cellular 
debris (bronchial-casts) 24 hours after the PDT treatment. A follow-up LIFE-bronchoscopy will 
be performed 6 weeks after PDT treatment and all treated lesions will be re-biopsied.  If a patient 
would be eligible to receive photodynamic therapy the procedure, risks and benefits will be 
discussed by the attending surgeon and the patient will sign a hospital consent form for that 
procedure. 
 
Patient Follow-up: 
Patient surveillance will consist of a repeat LIFE bronchoscopy. Patients who are found to have 
no abnormalities will have a follow-up bronchoscopy one year after the initial bronchoscopy.  
Those diagnosed with moderate to severe dysplasia will be assessed and re-biopsied in three 
months.  Those with CIS will be re-evaluated 6 weeks after Photodynamic Therapy treatment, 
with a repeat LIFE bronchoscopy and biopsy of the anatomic location of the treated lesion. 
 
BOISTATISTICAL DESIGN AND ANALYSIS: 
The number of biopsies taken in each patient will vary depending upon the identification and number of 
Class III areas visualized.  Previous experience with the LIFE-Lung endoscopy system, in conjunction 
with white light bronchoscopy (WLB) has found that the prevalence of moderate or severe dysplasia, or 
carcinoma in situ was 19% in patients that had a primary lung cancer completely resected.  We will 
assume our post-resection patients are similar and that the combined modality (WLB and LIFE) detection 
rate is 50% higher than WLB alone.  An increase in detection rate of moderate or severe dysplasia or 
carcinoma in situ using LIFE of less 20% would not represent a clinically meaningful improvement so 
that the study is designed to allow this possibility to be excluded with high probability. From Table 1: the 
probability that the null hypothesis that “LIFE increases the detection rate by only 20%” would be 
rejected if the true effect was that “LIFE increases the detection rate by 50%” (alternative hypothesis).  
This assumes that only one positive biopsy is obtained from each subject, multiple positive biopsies will 
increase the power of the study.  These statistics are based on a sample size of 250 patients which will 
provide good power at the  = 0.05 level. Over the past two years, 7/1/95 - 6/30/97, there have been 594  
lung resections performed at the University of Pittsburgh Medical Center by surgeons in the Section of 
Thoracic Surgery, and accrual of this number of post-resectional patients should not be difficult.  Previous 
clinical studies with the LIFE-Lung system have suggested that its false positive rate is similar to that of 
WLB, with neither technique having a particularly high rate, so that the power to test differences in their 
specificities will be low with the chosen sample size of 250 patients.  
 
One objective of this study is to measure the differences in the detection rate for moderate and severe 
dysplasia as well as CIS between LIFE-Lung fluorescence and WLB (reflective) bronchoscopy.  This will 
be calculated on a per-person and a per-lesion basis.  Confidence intervals will be calculated assuming 
these observations to be independent. Ratios between these quantities and values calculated for WL 
bronchoscopy alone will be computed.  The distribution of LIFE +/WLB - & LIFE -/WLB + lesions 
conditional to the total number of +ve lesions will be analyzed using a x2 test on both a per-person and 
per-lesion basis.  An important objective will be to determine the false positive rate of WLB and LIFE-
Lung bronchoscopy especially after PDT treatment of CIS lesions with Photophrin.   
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HUMAN SUBJECTS: No exclusion criteria shall be based on race, ethnicity, gender or HIV status. 
Lung 
National Native Amer/Eskimo Asian Blac
k 
Hispanic White Other  Overall 
Female 0.10 0.30 6.50 0.40 32.30 1.70 41.30 
Male 0.10 0.70 11.00 0.80 0.80 2.70 58.70 
Total 0.20 1.00 17.50 1.20 1.20 4.40 100.00 
University Health System Consortium (UHC) Database Calendar Year 1995 
 
Lung 
Local Native Amer/Eskimo Asian Blac
k 
Hispanic White Other  Overall 
Female 0.00 0.00 3.10 0.00 38.40 0.50 42.00 
Male 0.00 0.50 8.10 0.00 49.10 0.30 58.00 
Total 0.00 0.50 11.20 0.00 87.50 0.80 100.00 
University Health System Consortium (UHC) Database Calendar Year 1995 
 
ELIGIBILITY/INELIGIBILITY CRITERIA: 
Inclusion Criteria: 
1. Patients with NSCLC that have undergone  complete resection, via a lobectomy, pneumonectomy or 
wedge-resection, and who are currently NED. 
2. Patients with HNSCC that have undergone radical head and/or neck resection and who are currently 
NED. 
3. Patients with severe chronic, obstructive, pulmonary disease as evidenced by pulmonary function 
studies abnormalities: i.e. FEV1 < 50% predicted; RV > 200% predicted and/or DLCO < 40% predicted. 
Exclusion Criteria: 
  1.Patients with uncontrolled hypertension (systolic > 200 mm Hg, Diastolic pressure > 120 mm Hg). 
  2.Patients with unstable angina. 
  3.Patients with known or suspected pneumonia. 
  4.Patients with acute bronchitis within one month of the procedure. 
  5.Patients who have received neoadjuvant or adjuvant chemo- or radio-therapy within the past six 
months. 
  6.Patients with white blood count less than 2000 or greater than 20,000 and/or platelet count less than 
50,000. 
  7.Patients with any known bleeding dyscrasia. 
  8.Patients who have received fluorescent photosensitizing drugs such as Photofrin within one month of 
the procedure.  
  9.Patients with known allergic reactions to topical xylocaine. 
10.Patients who are on or have received chemopreventive drugs (i.e. retinoic acid) within one month of 
the procedure. 
11.Patients who have received ionizing radiation to the chest within six months of the procedure. 
12.Patients who have received systemic cytotoxic chemotherapeautic agents within the past six months. 
13.Patients who are pregnant or nursing. All women of childbearing potential must have a negative serum 
pregnancy test prior to enrollment. 
 
Sources of Research Material Patients who are seen in UPCI/UPMC clinics are identified as potential 
research subjects.  Other subjects are referred in specifically for possible participation in a particular study 
which they or their physician are aware of based on publications, which list clinical trials at UPCI by 
means of various publications, including the World Wide Web.  Such publications and Web listings are 
not advertisements for specific studies.  Rather, they are public listings of trials available. 
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Recruitment Methods and Consent Procedures.  Once a patient is identified as a potential participant in a 
research study as indicated in above, they are screened for eligibility.  Depending on whether the 
screening procedures are invasive or whether they involve tests that would not be done in the routine care 
of the patient, an appropriate consenting procedure would be carried out as follows: 
If the screening procedures are invasive and/or involve tests that would not be done for the routine 
clinical care of the patient, they would be asked to provide written informed consent before they are 
screened. 
If the testing to determine eligibility is such that would be done for routine clinical care, the potential 
subject would not be asked to sign a consent form until such time as they are determined to be legible for 
the study. 
In either case, the consent process would be carried out as a joint effort among the patient’s physician, the 
study coordinator, and/or the investigators on the study. 
 
Potential Risks. Patients who will be recruited into this study are those where a standard fiber-
optic bronchoscopy would be indicated either to establish the exact anatomic tumor location and 
rule out synchronous lesions (in patients with T1-T3,N0,M0 lesions) preoperatively or patients 
who have undergone a previous anatomic resection of their NSCLC primary and are not 
currently undergoing adjuvant therapy (within the past six months).  The specific risks associated 
with a standard bronchoscopic procedure include: 
 
Bleeding (usually mild and self-limiting): < 1:20,000. 
Drug reaction, including over-sedation: < 1.0%. 
Pneumonia, bronchitis or aspiration requiring therapy:  <1.0% 
Loss of teeth: < 1.0% 
 
As an adjunctive examination during a standard fiber-optic bronchoscopy, fluorescence examination with 
the LIFE-Lung system will carry similar potential risks.  Although the risk of an adverse drug reaction 
will already incurred with the standard fiber-optic bronchoscopy, the risk of bleeding secondary to 
additional biopsies will be additive. 
 
All patients will undergo WLB and LIFE-Lung bronchoscopy with continuous electrocardiographic and 
oximetric monitors.  If a patient develops a significant arrhythmia or sustained de-saturation below 90% 
on supplemental oxygen the procedure will be terminated.  The bronchoscopy suite will be fully equipped 
with emergency medical equipment and supplies.  Additional time to perform the LIFE-lung fluorescence 
examination is approximately thirty minutes.  There is no foreseeable risk to either patient population in 
extending the examination time approximately 30 minutes. 
 
Risks associated with photodynamic therapy primarily include: allergic reaction (7.7%) and 
photosensitivity (1.9%) after photophrin II injection, transient elevation of ALT (1.9%), and pulmonary 
toxicity (predominantly atelectasis) (7.7%). 
 
Risk Management Procedures.  Patients will be monitored at intervals as stipulated in the Methods 
section.  Appropriate care will be provided to patients who experience difficulty while being treated, and 
patients are encouraged in the consent forms to report adverse experiences to the investigators.  This 
information is collected per the protocol, and treatment is administered as needed. 
 
Evaluation of the Risk/Benefit Ratio. Evaluation is performed as per the statistical information in the 
protocol.  Any interim reports which are prepared by the investigatiors or received from the sponsor 
would be provided to the University of Pittsburgh IRB. 
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JUSTIFICATION FOR UTILIZATION OF GCRC RESOURCES: The principle investigator and 
protocol coordinator will meet on a three month interval to review data and adverse events and 
summarize with a progress report that will be given to the University of Pittsburgh IRB.  Any reports 
received by the sponsor will also be given to the IRB. 
 
RESEARCH NEEDS TO BE PROVIDED BY INVESTIGATOR’S OR OUTSIDE 
LABORATORY: (see elsewhere in text) 
 
FUNDING SUPPORT:  American Cancer Society – Pittsburgh Cancer Institute Grant, University of 
Pittsburgh Department of Surgery, National Cancer Institute/National Institutes of Health. 
 
COSTS AND PAYMENTS: 
LIFE-lung bronchoscopy will be performed in tandem with standard white light bronchosopy, the latter is 
a routine examination covered by insurance for patients with indications such as lung cancer, COPD, 
chronic cough, hemoptysis and other pulmonary symptoms.  No payment for participation will be given.  
The patients will be billed for a conventional bronchoscopy, the standard pathologic examination of 
biopsies and standard sputum cytology.  The patient will not be billed for the LIFE-lung bronchoscopy, 
the biopsies, or the molecular marker laboratory work relating to the biopsies, sputum or blood sample.  
PDT for T1 NSCLC is an FDA-approved treatment and covered by patient insurance as well.  
 
Molecular studies of biopsies obtained through LIFE Bronchoscopy are being sponsored by several 
research grants.  A group of investigators (the Lung Carcinoma Working Group) at UPCI is interested in 
studying these biopsies to obtain preliminary data for a Program Project Grant to examine early events in 
lung carcinogenesis.  These investigators include: Drs Jill Siefgried, Phoutone Keohavong, Marjorie 
Romkes, William Bigbee, and Sharon Shriver.  The UPCI Lung Cancer Basic Science Program is 
sponsoring a Pilot Project to Dr Phoutone Keohavong (total costs $20,650) to examine mutations in p53 
and K-ras genes in these specimens.  Dr Jill Siegfried has a grant from the NIH to study bombesian-like 
peptide receptors (direct costs $163,000 per year) and these funds will be used to examine these receptors 
in LIFE Bronchoscopy speciments.  Dr. Siegfried also has a grant from the American Cancer Society to 
study hepatocyte growth factor (HGF) which will cover the costs of measuring HGF in these specimens.  
She also has a grant from the Mark Ravitch/Leon C. Hirsch Center for Minimally Invasive Surgery for 
$24,640 to study molecular markers of pre-neoplasia/carcinoma in situ in the respiratory epithelium.  Dr 
Shriver has a pilot grant from the UPCI Lung Cancer Basic Science Program to study genes on 
chromosome three ($25,000 total costs) and these funds will also be used to study 3p deletions in the 
biopsies. All specimens will be stored at no cost in Dr Siegfried’s laboratory and DNA, RNA, and protein 
will be extracted there.  The extracted material will be shared among the investigators, with funded 
investigators receiving priority.  Because many of the biomarkers will be measured by PCR reaction, very 
little material will be required.  The biological sample or genetic material may lead, in the future, to new 
inventions or products.  If the research investigators are able to develop new products from the use of the 
patient’s biological sample or genetic material, there are currently no plans to share with the patient any 
money or other rewards that may result from the development of the new product. 
 
QUALIFICATIONS OF COLLABORATING INVESTIGATORS: 
 
Neil A Christie, MD, FRCS(C) is an Assistant Professor of Surgery in the School of Medicine at 
the University of Pittsburgh. He is a thoracic surgeon who also trained in cardiothoracic and 
general surgery. He has extensive clinical experience in thoracic oncology having completed a 
two-year fellowship in cardiothoracic surgery at The Cleveland Clinic Foundation.  
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James D. Luketich, MD is an Associate Professor of Surgery and Head of the Section of Thoracic 
Surgery at the University of Pittsburgh. He has extensive clinical experience in thoracic surgery. 
He has numerous publications covering many issues in thoracic surgery, however his main 
interest currently is surgical therapy for esophageal cancer. He is an associate member of the 
Pittsburgh Cancer Institute and is a clinical investigator with the Eastern Cooperative Oncology 
Group. 
Peter Ferson, MD is a Professor of Surgery at the University of Pittsburgh Medical Center in the 
Section of Thoracic Surgery. Previously he was the Chief of Cardiac Surgery at Montefiore 
Hospital. Dr. Ferson is currently then Chief of Thoracic Surgery at the VA Medical Center, and 
Director of Clinical Services. 
Percy Buenaventura 
Jennifer Ruben Grandis 
Jill Siegfried, PhD is an Associate Professor of Pharmacology in the School of Medicine at the 
University of Pittsburgh. She has extensive research experience in the cell biology of malignant 
transformation, and is particularly interested in growth factor and growth factor receptor 
interactions in malignancy, as well as genetic and molecular abnormalities in lung cancer. She 
has numerous collaborative efforts ongoing in the School of Medicine, as well as other 
institutions. She is also an associate member of the Pittsburgh Cancer Institute. 
Kelly Kraynick, RN, BSN is the Clinical Research Coordinator for the Section of Thoracic 
Surgery.  Her clinical experience includes one and a half years working as a staff nurse for 
neurosurgical and cardiothoracic patients.  Her research experience includes one and a half years 
at the University of Arizona, Sarver Heart Center, working as a Clinical Research Coordinator 
for the Cardiovascular Protocols and working two years with Diabetic Neuropthy Protocols for 
the University of Pittsburgh, Department of Neurology. 
Sue Churma, RD CNSD is the Research Dietitian for the Section of Thoracic Surgery. Her 
clinical experience includes four years as an inpatient oncology dietitian, and also four years 
working as inpatient and outpatient dietitian for the Section of Thoracic Surgery. Her research 
experience includes two years with the Lung and Esophageal Photodynamic Therapy program 
with the Section of Thoracic Surgery. She has also helped with the LIFE program during its first 
stages of development. 
Patty Mantia, RN  Thoracic Specialist of University of Pittsburgh Medical Center. Her clinical 
experience includes sixteen years as an Operating Nurse for UPMC Presbyterian. Her 
responsibilites include coordinating care of patients and staff for the Thoracic Surgery Division. 
Her research experience includes the collection and documentation of specimens in the operating 
room which includes those in the LIFE protocol. She is also responsible for specimen and data 
collection for other current studies. 
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  NULL HYPOTHESIS  
Prevalence of moderate or severe 
dysplasia or CIS 
with white light bronchoscopy 
20% more lesions found using LIFE-Lung 
Fluorescence Endoscopy 
 a=0.05 a=0.01 
0.10 0.81 0.61 
0.20 0.98 0.93 
 
Table 1 
Estimated Power for Study Design Enrolling 250 Patients Under the Alternative Hypothesis that 
50% More Disease is Identified Using LIFE Fluorescence Endoscopy. 
 127
  
APPENDIX C 
 
 
 
 
MATLAB MIE LIBRARY CODE 
 
 
 
 
%BEGIN Original source file build_library6.m 
%This function builds a disk-based library of calcuated Mie scattering coefficients 
%for an ideal sphere of the given diameter(s) with a given refreactive index 
%and located in the given media.  
%The function name and parameters has been preserved so that 
%they are consistent with the original text in 
%Bohren & Huffman, "Absorption and Scattering of Light by Small Particles", 
%Wiley Interscience, 1983 
%It is intended for other functions to load the Mie curves as needed from the 
%disk.  
 
function  build_library6(ref_med, ref_bead, diameter_list);  
%A usage example....  
           if (nargin==0)  
               ref_med = 1.33; %water  
               ref_bead = 1.59; %polystyrene  
               diameter_list = [1.025 0.505 0.495]; %um;  
           end  
           starttime=now;  
           for d=diameter_list;  
               if (exist(curvelib6path(ref_med,ref_bead,d))~=2)  
                   save_callbm(d,ref_med,ref_bead);  
               else  
                   disp(sprintf('Skipping %dmm...',d));  
               end  
           end  
           disp('Done.');  
           disp('Starting Time');  
           disp(datestr(starttime,0));  
           disp('Ending Time');  
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           disp(datestr(now,0));  
 
function  save_callbm(diameter,ref_med, ref_bead);  
           nang=901;  
%radii = 1:0.5:20; 
           radii = [diameter]/2; %diameters  
           if (1==0)  
            waves = (380:1:1500)*0.001;  
           else  
            waves = (380:1:690)*0.001;      
           end  
%Note: Thetas are specified in degrees 
%thetas = [165:180]; 
%distance = 7; 
%dtheta_i = atan(0.4/distance) 
%dtheta_r = atan(0.175/distance); 
           dtheta = 90/(nang-1);% = 0.1  
%dtheta1 = ceil(dtheta_i/dtheta) 
%dtheta2 = ceil(dtheta_r/dtheta) 
%thetas = 165:dtheta:180; 
           starttheta=1;  
%disp('Precomputing Sphere Scattering'); 
%disp('For thetas'); 
%disp(thetas); 
%disp('For lambdas'); 
%disp(waves); 
%disp('For radii'); 
%disp(radii); 
           callbm_results.radii=radii;  
           callbm_results.dradius=0.1;  
           callbm_results.waves=waves;  
           callbm_results.dwave = waves(2)-waves(1);  
           callbm_results.units = 'um';  
           callbm_results.dtheta=dtheta;  
%callbm_results.distance=distance; 
           callbm_results.thetas = starttheta:dtheta:180;  
           rslt = [];  
%r_checkpoint = 
[radii(1),radii(floor(0.25*length(radii))),radii(floor(0.5*length(radii))),radii(floor(0.75*length(ra
dii)))] 
           r_checkpoint = [0];  
           disp(sprintf('Building %s',curvelib6path(ref_med,ref_bead,diameter)));  
           for r=length(radii):-1:1  
              rad=radii(r);  
              ttl = sprintf('Radius=%6.3fnm',rad);  
%   set(FH,'name',sprintf('Wave=%6.3fnm',wav*1000)); 
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              disp(sprintf('--------- Radius=%6.3f---------- (begun at %s)',rad,datestr(now,0)));  
              gall=[];  
              for w=length(waves):-1:1  
                 wav = waves(w);  
                 disp(sprintf('--------- Radius=%6.3f, Wave=%6.3f ----------',rad,wav));  
%      [gy,gx]=makeGaussian(rad,ss); 
%  gy = [1 1 1]; 
%  gx=[rad-1 rad rad+1]; 
%      glen = length(gx); 
                    [ts1,ts2,tres]=doParams(wav,rad,nang);  
                    temp_res=[ts1,ts2,tres];  
                    gall(w,:,:)=temp_res((floor(starttheta/dtheta)):end,:);  
              end  
%   subplot(2,1,r); 
%   plotResults(ttl,rslt,waves,thetas); 
%return; 
              rslt(r,:,:,:)=gall(:,:,:);  
%   if (sum(r==r_checkpoint)>0) 
%      callbm_results.res=rslt; 
%      disp(sprintf('Saving checkpoint at %%%d...',floor(100*(r/length(radii))))); 
%      save 'callbm_JQE_checkpoint' callbm_results 
%      callbm_results = rmfield(callbm_results,'res'); 
%   end 
           end  
%Note that data is in the format (radius,wavelength,:,:) 
%(:,1) is s1, (:,2) is s2, (:,3) is theta, etc. 
           disp('Generation complete. Saving...');  
           callbm_results.res=rslt;  
           save (sprintf('curvelib\%s',curvelib6path(ref_med,ref_bead,diameter)),'callbm_results');  
 
function  pl=printResults(ang,s1,s2,res);  
           len = length(s1)  
           disp(sprintf('Ang'));  
%th=floor(res(:,1)); 
           pl=zeros([length(ang),3]);  
           p=1;  
           for k=1:len,  
              if (find(ang==floor(res(k,1))))  
                 pl(p,1)=res(k,1);  
                 pl(p,2)=s1(k);  
                 pl(p,3)=s2(k);  
                 p=p+1;        
                 disp(sprintf('%6.2f%13.6f%16.3f',res(k,1),s1(k),s2(k)));  
              end  
           end  
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function  [s1,s2,res]=doParams(wavel,rad,nang);  
           refmed = 1.33;  
           refbead = 1.59;  
%refrel = complex(1.59,0)/refmed; 
           refrel = complex(refbead,0)/refmed;  
%refrel=computeRefRel(wavel*1000); 
%[refbead,refmed,refrel]=computeRefRelPSB3(wavel); 
%disp(sprintf('RefMed=%8.4f, refre=%f, refim=%f',refmed,real(refrel),imag(refrel))); 
%rad=0.525; 
%wavel=0.6328; 
           x=2*3.14159265*rad*refmed/wavel;  
%x=2*3.14159265*rad/wavel; 
%disp(sprintf('Sphere Radius=%7.3f, wavelength=%7.4f, size param=%8.3f',rad,wavel,x));  
           dang=1.570796327/(nang-1);  
           [s1,s2,qext,qsca,qback]=bhmie(x,refrel,nang);  
%disp(sprintf('Qsca=%13.6f, Qext=%13.6f. Qback=%13.6f',qsca,qext,qback)); 
           res=[];  
           return;  
           s11nor=0.5*(abs(s2(1))^2+abs(s1(1))^2);  
%disp(sprintf('Ang')); 
           len = (2*nang-1);  
           res=double(zeros([len 5]));  
           for j=1:len,  
              t1 = abs(s2(j))^2;  
              t2 = abs(s1(j))^2;  
              s11=0.5*(t1 + t2);  
              s12=0.5*(t1 - t2);  
              pol=-s12/s11;  
              t3 =s2(j)*conj(s1(j));  
              s33=real(t3)/s11;  
              s34=imag(t3)/s11;  
              s11=s11/s11nor;  
              ang=dang*(j-1)*57.2958;  
              res(j,:)=[ang s11 pol s33 s34];  
%  disp(sprintf('%6.2f%13.6f%13.6f%13.6f%13.6f',ang,s11,pol,s33,s34)); 
           end  
 
function  [iSphere,iMedium,refrel]=computeRefRelPSB3(wavel);  
%im = [1.3231; 0; 3.3e-3; 0; -3.2e-5]; %Mcneil 
           im = [1.31279; 15.762e-3; -4.382e-3; 1.1455e-3;0]; %Quan & Fry  
           is = [1.5663; 0; 7.85e-3; 0; 3.34e-4]; %From Duke Scientific  
%is = [1.5725; 0; 3.108-3; 0; 3.34e-4];  %From paper 
           wl = [1,1/wavel,1/(wavel.^2),1/(wavel.^3),1/(wavel.^4)];  
           iSphere = wl * is;  
           iMedium = wl * im;  
           refrel = iSphere/iMedium;  
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function  [iSphere,iMedium,refrel]=computeRefRelPSB(wavel);  
           im = [1.3236; 0; 3.3418e-3; 0; -3.45e-5];  
%is = [1.5663; 0; 7.85e-3; 0; 3.34e-4]; 
           is = [1.5725; 0; 3.108-3; 0; 3.34e-4];  
           wl = [1,1/wavel,1/wavel^2,1/wavel^3,1/wavel^4];  
           iSphere = wl * is;  
           iMedium = wl * im;  
           refrel = iSphere/iMedium;  
 
function  refrel=computeRefRel(wavel);  
           im = [1.413; -0.0002968; 3.679e-7; -1.614e-10];  
           is = [1.896; -0.001185; 1.544e-6; -7.022e-10];  
           wl = [1,wavel,wavel^2,wavel^3];  
           iSphere = wl * is;  
           iMedium = wl * im;  
           refrel = iSphere/iMedium;  
%END Original source file build_library6.m 
%BEGIN Original source file bhmie.m 
%This code was adapted from the original FORTRAN code in 
%Bohren & Huffman, "Absorption and Scattering of Light by Small Particles", 
%The function name and parameters has been preserved so that 
%they are consistent with the original text. 
 
function  [s1,s2,qext,qsca,qback]=bhmie(x,refrel,nang);  
           y=x*refrel;  
           xstop=x+(4*x^0.3333)+2;  
           nstop=xstop;  
           ymod=abs(y);  
           nmx=floor(max([xstop ymod]))+15;  
           dang = 1.570796327/(nang-1);  
           for j=1:nang,  
               theta(j)=(j-1)*dang;  
           end  
           amu=cos(theta);  
           d(nmx)=0+0i;  
           for n=1:(nmx-1);  
               rn=nmx-n+1;  
               t4=rn/y;  
               d(nmx-n)=t4-(1/(d(rn)+t4));  
           end  
           pi0=zeros([nang 1]);  
           pi1=ones([nang 1]);  
           s1=complex(zeros([(2*nang-1) 1]));  
           s2 = s1;   
           psi0=cos(x);  
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           psi1=sin(x);  
           chi0=-sin(x);  
           chi1=cos(x);  
           xi0=complex(psi0,-chi0);  
           xi1=complex(psi1,-chi1);  
           qsca=0.0;  
           n=1;  
           P=-1;  
           for n=1:nstop;  
               fn=(2*n+1)/(n*(n+1));  
               psi=(2*n-1)*psi1/x-psi0;  
               chi = (2*n-1)*chi1/x-chi0;  
               xi=complex(psi,-chi);  
               t5=d(n)/refrel+n/x;  
               an = (t5*psi - psi1)/(t5*xi - xi1);  
               t6=d(n)*refrel+n/x;  
               bn = (t6*psi - psi1)/(t6*xi - xi1);  
%    qsca=qsca+(2*n+1)*( abs(an)^2+abs(bn)^2); 
               qsca=qsca+(2*n+1)*( (an *conj(an))+ (bn *conj(bn)));  
%angles 0-90 deg 
               for j=1:nang;  
                   pi_(j)=pi1(j);  
                   tau(j)=n*amu(j)*pi_(j) - (n+1)*pi0(j);  
                   s1(j)=s1(j)+fn*(an*pi_(j)+bn*tau(j));  
                   s2(j)=s2(j)+fn*(an*tau(j)+bn*pi_(j));  
               end;  
%angles 90+ 
               P=-P;  
               for j=1:(nang-1);  
                   jj=2*nang-j;  
                   s1(jj)=s1(jj)+fn*P*(an*pi_(j)-bn*tau(j));  
                   s2(jj)=s2(jj)+fn*P*(bn*pi_(j)-an*tau(j));  
               end  
               psi0=psi1;  
               psi1=psi;  
               chi0=chi1;  
               chi1=chi;  
               xi1=complex(psi1,-chi1);  
%update 
%     figure(99); 
%     clf; 
%     plot(1:length(s1),s1 .* conj(s1)); 
%     title(sprintf('Pass #%d',n)); 
%     pause; 
%computer pi_n for next value of n 
               for j=1:nang,  
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                   pi1(j) = ( (2*n+1)*amu(j)*pi_(j)-(n+1)*pi0(j) )/n;  
                   pi0(j)=pi_(j);  
               end  
           end  
           qsca=(2/(x*x))*qsca;  
           qext=(4/(x*x))*real(s1(1));  
%qback=(4/(x*x))*s1(2*nang-1)*conj(s1(2*nang-1)); 
           qback=((abs(s1(2*nang-1))/x)^2)/pi;  
%END Original source file bhmie.m 
%BEGIN Original source file curvelib6path.m 
%This function is an abstracted version of the library name so that other 
%matalb functions can easily figure out what the Mie curve's filename is. 
 
 
 
function  path=curvelib6path(ref_med,ref_bead,d);  
           path=sprintf('curve-library6-%d-%d-
d%04dmm.mat',floor(ref_med*100),floor(ref_bead*100),floor(d*1000));  
%END Original source file curvelib6path.m 
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